• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention provides 1,4-dihydropyridine derivatives of formula (I) wherein R
    公开号:AU2012342226A1
    申请号:U2012342226
    申请日:2012-11-22
    公开日:2014-06-19
    发明作者:Gabor Balogh；Sandor Bernath；Ferenc Fulop；Ibolya Horvath；Akos Hunya；Botond Penke；Zsolt Torok；Laszlo Vigh
    申请人:LIPIDART KUTATO FEJLESZTO ES TANACSADO KFT；
    IPC主号:C07D211-80
    专利说明:
    WO 2013/076516 PCT/HU2012/000126 1,4- DIHYDROPYRIDINE DERIVATIVES WITH HSP MODULATING ACTIVITY BACKGROUND OF THE INVENTION 5 1. Technical Field of the invention The invention relates to partly new compounds which are useful as pharmaceuticals, to pharmaceutical and cosmetical compositions containing new compounds and to such compounds for the use in the treatment and prevention of pathophysiological conditions and diseases either mediated or influenced by heat shock proteins (Hsps) also termed stress proteins. More particu 10 larly the invention relates to certain 1,4-dihydropyridines with selective Hsp modulating activity both in vitro and in vivo, and to the use of such compounds in the field of the treatment and pre vention of pathophysiological conditions mediated by Hsps, including for example neurodegen erative diseases, cancer, metabolic syndromes, diabetes, obesity, inflammation and skin diseases, as well as diseases and/or disorders that would benefit from altered Hsp function in various 15 metabolic or environmental stress conditions and to pharmaceutical and cosmetical compositions comprising such compounds. 2. Description of the Prior Art Heat shock proteins (Hsps) belong to functionally related proteins whose cellular amount 20 changes when cells are exposed to elevated temperatures or other stresses (Goldberg et al., Na ture, 426: 895-899, 2003) ranging from hypoxia, inflammation, or infections to environmental pollutants. Certain Hsps may also function as molecular chaperones under normal stress-free conditions by regulating the correct folding and function of numerous important cellular pro teins. 25 Major heat-shock proteins are grouped according to their molecular weight (Hsp 100, Hsp 90, Hsp70, Hsp60, and the "small Hsps", sHsps). Some members of the Hsp family are expressed at low to moderate levels in all organ isms because of their essential role in protein maintenance. Due to their multiple and vital func tions, Hsps play fundamental roles in the aetiology of several human diseases (Solti et al., Br. J. 30 Pharmacol., 146: 769-780, 2005). For example aberrantly high levels of either the overall array of Hsps, or certain Hsp classes are characteristic in different cancer cells and the converse ap plies typically for type 2 diabetes, neurodegeneration, cardiovascular diseases or aging (Vigh et al.; Prog. Lipid Res., 44(5): 303-344, 2005 and Vigh et al.; Trends Biochem. Sci., 32: 357-363, 2007).
    WO 2013/076516 PCT/HU2012/000126 35 In order to highlight the mechanism of action of the different Hsp classes and to provide compounds moderating their activity and being suitable for drug development a large number of investigations have been undertaken over the last decade. Hsp 70 40 The evolutionary conserved Hsp70 chaperone family and its co-chaperones with the ex ception of some archaea (Large et al., Biochem. Soc. Trans. 37: 46-51, 2009), are present in all ATP-containing compartments of living organisms (Macario et al., Genetics, 152:1277-1283, 1999). The functional Hsp70 chaperone network entails ATP-driven interactions among many diverse substrate-specific and less specific J-domain co-chaperones (49 in human) that target the 45 fewer Hsp70 isoforms (Kampinga et al., Cell Stress Chaperones, 14:105-111, 2009) onto hun dreds of protein substrates in the cell and are regulated by various nucleotide exchange factors such as glucose regulated protein E (GrpE) (Harrison, Cell Stress Chaperones 8:218-224, 2003), BAG (Kabbage et al., Cell Mol Life Sci., 65: 1390-1402, 2008), HspBP1 (Kabani et al., FEBS Lett., 531:339-342, 2002), and Hsp1 10 proteins (Shaner et al., Cell Stress Chaperones, 12:1-8, 50 2007). These networks are crucial to the co-translational folding of nascent polypeptides, the re modelling of native protein complexes, the transduction of cellular signals, the regulation of the cell cycle, proliferation and apoptosis (Jolly et al., J. Natl. Cancer Inst., 92:1564-1572, 2000), the regulation of the heat shock response, the unfolding and refolding of stress-denatured proteins, and the import of proteins into the mitochondria (De Los Rios et al., Proc Natl Acad Sci U S A, 55 103:6166-6171, 2006), chloroplasts (Shi et al., Plant Cell, 22:205-220, 2010), and the endoplas mic reticulum (reviewed in Zimmermann et al., Biochim Biophys Acta, 1808:912-924, 2011). In normal cells, quality control systems prevent the accumulation of toxic misfolded pro tein species. However, in response to mutagenesis, aging or oxidative stress, misfolding can of ten occur escaping quality control (Soskic et al., Exp. Gerontol., 43: 247-257, 2008; Zeng et al., 60 Mech. Ageing Dev., 126: 760-766, 2005; Shpund & Gershon, Arch. Gerontol. Geriatr., 24: 125-131, 1997). As postmitotic cells, neurons appear to be particularly sensitive to these effects and many neurodegenerative disorders, such as Alzheimer's, Parkinson's, and Huntington's diseases, in volve aberrant accumulation of misfolded or misprocessed proteins. Genetic studies have rou 65 tinely linked Hsp70 and its co-chaperones to this process, and thus, it has emerged as a potential drug target (Evans et al., J Med Chem., 53:4585-4602, 2010). Alzheimer's disease (AD) is the most common neurodegenerative disease, and its patients are characterized by progressive mem ory loss and the accumulation of senile plaques (SP) composed of p-amyloid (AP) and neurofi brillary tangles (NFTs) assembled from tau. Current models suggest that self-association of AB 2 WO 2013/076516 PCT/HU2012/000126 70 or tau into P-sheet rich oligomers leads to neuronal cell death. Hsp70 has been shown to play important roles in the cytotoxicity of both AP and tau (for review see (Evans et al., J Med Chem., 53:4585-4602, 2010). For example, Hsp72 blocks the early stages of AP aggregation in vitro at substoichiometric levels (Evans et al., J Biol Chem., 281:33182-33191, 2006), and Hsp70 has been shown to alter processing of the amyloid precursor protein (Kumar et al., Hum 75 Mol Genet., 16:848-864, 2007). Also, this chaperone protects against AP-induced cytotoxicity via inhibiting caspase-9 and accelerating the elimination of AP (Veereshwarayya et al., J Biol Chem., 281:29468-29478, 2006). In addition to these effects on AP, Hsc70 also binds tau at two sites within its tubulin-binding repeats, which is the same region required for tau self-association (Sarkar et al., J Neurosci Res., 86(12):2763-2773, 2008). This finding suggests that Hsc70 might 80 compete with aggregation and toxicity and, consistent with this model, overexpression of Hsp70 reduces aggregated tau in mouse models (Petrucelli et al., Hum Mol Genet., 13:703-714, 2004). Pharmacological upregulation of Hsp70 expression Many pharmacological agents have been demonstrated to increase cellular expression of 85 Hsp70 through various mechanisms (Sloan et al., Curr Opin Drug Discov Devel., 12:666-681, 2009). A distinction should, however, be made between molecules that act by a defined stimula tion within the Hsp70 regulatory pathway and those that affect Hsp70 levels by introducing a cellular stress. Compounds that use the latter stress-inducing mechanism may have a higher pro pensity to cause cell death or other unwanted effects as a result of chronic stressing, and thus 90 may be less desirable as therapeutic agents. A further distinction of the modes of action of differ ent Hsp70 upregulators can be made between Hsp70 inducers, which increase Hsp70 expression under a broad range of stress conditions, and Hsp70 co-inducers, which act solely to potentiate a pre-existing stress response and have little or no effect in non-stressed or healthy systems. The co-inducer mechanism may therefore selectively exhibit an effect in diseased tissue, thereby in 95 herently reducing the risk of unwanted side effects in healthy tissue (Sloan et al., Curr Opin Drug Discov Devel., 12:666-681, 2009). Modulators of protein processing Proteasome inhibitors such as bortezomib (Lauricella et al., Apoptosis, 11:607-625, 100 2006), MG-132 and lactacystin (Kim et al., Biochem Biophys Res Commun., 264:352-358, 1999) demonstrate significant HSF-1-mediated Hsp70 induction via inhibition of protein degra dation, accumulation of unfolded protein and induction of the cellular stress response (Sloan et al., Curr Opin Drug Discov Devel., 12:666-681, 2009). Lactacystin selectively induces the heat shock response (HSR) in preference to the unfolded protein response, and reduces nuclear inclu 3 WO 2013/076516 PCT/HU2012/000126 05 sions in a neuronal P1 27Q Huntington's disease model (Kim et al., J Neurochem., 91:1044-1056, 2004). In many cases, Hsp70 induction is accompanied by other, mechanism-based and undesir able cellular effects or apoptosis (Sloan et al., Curr Opin Drug Discov Devel., 12:666-681, 2009). Although proteasome inhibitors are approved for clinical use in oncology, their limited therapeutic window may preclude significant applicability of these drugs in the treatment of pro 10 tein-folding diseases. Chemically reactive inducers Chemical induction of Hsp70 has been described about N-ethylmaleimide (Senisterra et al., Biochemistry, 36:11002-11011, 1997), electrophilic serine protease inhibitors such as 3,4 15 -dichloroisocoumarin (DCIC) and N-a-tosyl-L-lysine chloromethyl ketone (TLCK) (Rossi et al., J Biol Chem., 273:16446-16452, 1998), curcumin, a major constituent of turmeric (Dunsmore et al., Crit Care Med., 29:2199-2204, 2001), cyclopentenone PGs, characterized by PGAI, A7 -PGA1, PGA2 and A12-PGJ2 (Lee et al., Proc Natl Acad Sci U S A, 92:7207-7211, 1995). The cyclopentenone PGs-are able to induce Hsp70 and are reported to induce HSF- 1 ac 120 tivation (7- to 15-fold) (Hamel et al., Cell Stress Chaperones, 5:121-131, 2000). Sodium salicy late enhances Hsp70 induction in spinal cord cultures (1 mM/40'C) compared with heat shock alone, and indomethacin reduces the temperature required for HSF-1 activation in HeLa cells under heat shock conditions at a dose of 250 M. This activity of indomethacin correlates with an increase in HSF-1 phosphorylation and a cytoprotective effect in HeLa cells; pretreatment 125 with indomethacin (250 pM/40'C) improved cellular survival rate of a subsequent 44.5'C heat shock from 3% with no pretreatment to approximately 40% (Lee et al., Proc Natl Acad Sci U S A, 92:7207-7211, 1995). Recent evidence has also suggested that PPAR7 agonists may have utility other than their well-characterized insulin sensitizing effects in Hsp-dependent processes: the reduction of Hsp70 130 inducibility observed in the heart of an insulin-resistant rat model was ameliorated by treatment (10 mg/kg/day) with the PPARy agonist pioglitazone. Additional reperfusion experiments also demonstrated that pioglitazone assisted functional recovery in isolated rat hearts (Taniguchi et al., Diabetes, 55: 2371-2378, 2006). Celastrol, a quinine methide triterpene isolated from preparations used in Chinese herbal 135 medicine, potently co-induces Hsp70 in concert with other stresses via an HSF-1-dependent mechanism (Westerheide et al., J Biol Chem., 279:56053-56060, 2004). This drug has demon strated neuroprotection in Huntington's models of polyQ aggregation (Zhang et al., J Mol Med., 85:1421-1428, 2007), and cytoprotection in mouse transgenic models of amyotrophic lateral sclerosis (Kiaei et al., Neurodegener Dis., 2:246-254, 2005). Several other natural products in 4 WO 2013/076516 PCT/HU2012/000126 40 cluding the triterpenoid enones glycyrrhizin (Yan et al., Cell Stress Chaperones, 9:378-389, 2004) and carbenoxolone (Nagayama et al., Life Sci., 69:2867-2873, 2001), as well as the masked acetal paeoniflorin (Yan et al., Cell Stress Chaperones, 9:378-389, 2004), may induce Hsp70 by similar mechanisms to celastrol. 145 Co-inducing hydroxylamine derivatives A family of hydroxylamine derivatives, including the prototype bimoclomol, were identi fied as co-inducers of the HSR with utility in a range of disease models-(Vigh et al., Nat Med., 3:1150-1154, 1997). Treatment of myogenic rat H9c2 cells with bimoclomol (10 ptM) 16h prior to heat shock resulted in a 4-fold increase in Hsp70 levels relative to heat shock alone (Vigh et 150 al., Nat Med., 3:1150-1154, 1997), with this induction providing cytoprotection (at 100 pM) in rat neonatal cardiomyocytes undergoing a lethal heat shock (Polakowski et al., Eur J Pharmacol., 435:73-77, 2002). The mechanism of action is thought to be via binding and modulation of phosphorylation of HSF-1 leading to effects on HSF-1/DNA binding (Hargitai et al., Biochem Biophys Res Commun., 307:689-695, 2003), although additional effects related to stabilization 155 of membranes during heat shock have been noted (Torok et al., Proc Natl Acad Sci U S A, 100:3131-3136, 2003). The bimoclomol analog BRX-220 has been demonstrated to significantly elevate Hsp70 level relative to vehicle in neurons following trauma (Kalmar et al., Exp Neurol., 176:87-97, 2002). The free base of BRX-220, arimoclomol, also delayed the progression of an amyotrophic 160 lateral sclerosis phenotype in a mouse model (Kalmar et al., J Neurochem., 107:339-350, 2008; Kieran et al., Nat Med., 10:402-405, 2004). Another hydroxylamine derivative NG-094 significantly ameliorated polyQ-mediated animal paralysis in C. elegans model, reduced the number of Q35-YFP aggregates and delayed polyQ-dependent acceleration of aging (Haldimann et al., J Biol Chem., 286:18784-18794, 165 2011). Metabolites and nutrients Relatively high doses of several metabolites and nutrients have also exhibited effects on Hsp levels, with associated functional benefits: a-lipoic acid ameliorated Hsp70 deficiency in pa 170 tients with Type 1 diabetes (Strokov et al., Bull Exp Biol Med., 130:986-990, 2000); and studies in brains of aged rats demonstrated increased Hsp expression (Hsp70 and heme oxygenase) in response to dosing with acetyl-l-camitine, a compound that is found in mitochondrial membranes (Calabrese et al., Antioxid Redox Signal, 8:404-416, 2006). 5 WO 2013/076516 PCT/HU2012/000126 Teprenone utilized in gastric ulcer treatment is a well-characterized inducer of Hsp70 that 75 has exhibited cytoprotective benefit in several models including gastric necrosis (Tomisato et al., Biol Pharm Bull., 24:887-891, 2001), cerebral infarction (Nagai et al., Neurosci Lett., 374:183 188, 2005), hepatotoxicity (Nishida et al., Toxicology, 219(1-3):187-196, 2006) and inflamma tion (Mochida et al., J Clin Biochem Nutr., 41:115-123, 2007). Other chaperones, including HspB8 (Sanbe et al., PLoS ONE, 4:e5351, 2009), are also induced by teprenone, which may fur 80 ther contribute to the cytoprotective properties of the molecule. Carvacrol, a major compound in oil of many Origanum species, had a capacity to co-induce cellular Hsp70 expression in vitro (Wieten et al., Arthritis Rheum., 62:1026-1035, 2010). Carvacrol specifically promoted T cell recognition of endogenous Hsp70 as was shown in vitro by the activation of an Hsp70-specific T cell hybridoma and amplified T cell responses to Hsp70 in vivo (Wieten et al., Arthritis Rheum., 185 62:1026-1035, 2010). Miscellaneous Hsp70 inducers The SirT-1 activator resveratrol induces Hsp70 and exhibits cytoprotection in response to heat shock and hydrogen peroxide treatment in human peripheral lymphocytes (Putics et al., 190 Antioxid Redox Signal, 10:65-75, 2008). Riluzole, an FDA approved drug for the treatment of amyotrophic lateral sclerosis, dem onstrated a co-induction of Hsp70 in a reporter gene assay with heat shock. This effect, which was ablated in HSF-1 knockout cells, was thought to be caused by a stabilization of the cytosolic HSF-1 pool (Yang et al., PLoS ONE, 3:e2864, 2008). 195 Elesclomol has demonstrated efficacy in Phase II clinical trials for the treatment of me tastatic melanoma by increasing the quantity of reactive oxygen species (ROS) in cells and selec tively inducing apoptosis in hypoxic tumour cells. This effect was accompanied by a tumour cell-specific increase in hypoxic tumour cells (Revill et al., Elesclomol. Drugs Future (2008) 33:310-315), however, development of this drug was recently suspended because of safety con 200 cerns. Other compounds that act to induce Hsp70 through sometimes incompletely character ized mechanisms include ectoine, a natural product isolated from halophilic microorganisms (Buommino et al., Cell Stress Chaperones, 10:197-203, 2005), diazoxide (O'Sullivan et al., J Neurotrauma, 24:532-546, 2007), and imidazothiadiazole (Salehi et al., Chem Biol., 13(2):213 205 -223, 2006). Many of the Hsp70 inducers described above may rely on the covalent modification of proteins for their mode of action, and could lead to initiation of the HSR, which may be prob lematic because of non-specific effects and immunogenicity. In some cases, molecules may sim 6 WO 2013/076516 PCT/HU2012/000126 ply be cell stressors, activating the cellular defence mechanisms including Hsp expression. This 10 chronic stressing of cells may deliver short-term efficacy, but the long-term effects on cellular response and viability are less easily predicted Co-inducer compounds that potentiate the re sponse to a pre-existing stress without exhibiting effects in non-stressed environments may pro vide a higher degree of tissue selectivity compared with non-specific stressors by acting to po tentiate pre-existing but inadequate stress responses to ongoing disease-related stress. 215 Genetic upregulation of Hsp7O The augmentation of Hsp70 has demonstrated beneficial effects in several overexpression studies, and in many cases has been associated with cytoprotection or attenuation of stress induced injury (Broome et al., FASEB J., 20:1549-1551, 2006; Choo-Kang et al., Am J Physiol 220 Lung Cell Mol Physiol., 281:L58-68, 2001; Chung et al., Proc Natl Acad Sci U S A, 105(5):1739-1744, 2008; Marber et al., J Clin Invest., 95:1446-1456, 1995; Muchowski et al., Proc Natl Acad Sci U S A, 97:7841-7846, 2000; Zheng et al., J Cereb Blood Flow Metab., 28:53-63, 2008). The exposure of cells or whole organisms to temperatures in excess of 40'C ('heat stressing') causes the upregulation of chaperones, including Hsp70. Many different com 225 pensatory mechanisms are activated during heat stressing, and therefore, it is difficult to assess which effects are caused solely by Hsp70. In order to overcome this challenge, mice that overex press solely the rat Hsp70 on promotion with p-actin have been developed. In these transgenic mice the overexpression of the rat inducible 70-kD heat stress protein increases the resistance of the heart to ischemic injury (Marber et al., J Clin Invest., 95:1446-1456, 1995). In another study, 230 Hsp72 overexpressing mice exhibited resistance to diet-induced hyperglycemia (Chung et al., Proc Natl Acad Sci U S A, 105:1739-1744, 2008), and a reduction in age-related markers of oxi dative stress (lipid peroxidation, glutathione content, superoxide dismutase and catalase levels) (Broome et al., FASEB J., 20:1549-1551, 2006). An increased expression (- 10-fold) of specific isoforms of Hsp70 has also been demonstrated in Hsp70 overexpressing mice, and was accom 235 panied by a reduced susceptibility to brain ischemia/reperfusion injury (Zheng et al., J Cereb Blood Flow Metab., 28:53-63, 2008). This protection from brain ischemia was accompanied by a reduction in the activation of NFicB throughout the brain as a whole, suggesting that Hsp70 may ameliorate ischemic injury by reducing inflammatory processes (Zheng et al., J Cereb Blood Flow Metab., 28:53-63, 2008). The effect of the overexpression of Hsp70 on discrete protein 240 folding processes has been demonstrated in an in vitro model of Huntington's disease, the aggre gation of the huntingtin protein bearing extended polyglutamine repeats was significantly re duced in yeast that overexpressed Hsp70 (or Hsp40), suggesting a direct role for these chaper 7 WO 2013/076516 PCT/HU2012/000126 ones in preventing the misfolding and/or aggregation of this pathogenic protein (Muchowski et al., Proc Natl Acad Sci USA, 97:7841-7846, 2000). 245 Similarly, in a cell model of cystic fibrosis, trafficking of the cystic fibrosis transmem brane conductance regulator (CFTR) containing the misfolding-prone AF508 mutant could be normalized in IB-3 cells with plasmid-induced overexpression of Hsp70, implying that Hsp70 has a role in chaperoning and correctly folding the mutant CFTR, enabling it to be trafficked to the cell surface (Choo-Kang et al., Am J Physiol Lung Cell Mol Physiol., 281:L58-68, 2001). 250 Small Hsps Unlike the ATPase chaperones HsplOO, Hsp90, Hsp70, and Hsp60, the small Hsps (sHsps) with a conserved a-crystalline domain that passively binds misfolded intermediates, in dependently from ATP hydrolysis (Jakob et al., J Biol Chem., 268:1517-1520, 1993). Without 255 stress, sHsps are mostly assembled into large oligomeric complexes (Garrido et al., Cell Cycle, 5:2592-2601, 2006), which, under stress conditions, may dissociate into amphiphilic dimers that prevent misfolding polypeptides from aggregating (Jakob et al., J Biol Chem., 268:1517-1520, 1993) and protect membranes from heat disruption (Haslbeck et al., Nat Struct Mol Biol., 12:842-846, 2005; Horvath et al., Biochimica et Biophysica Acta (BBA) - Biomembranes, 260 1778:1653-1664, 2008). sHsps cooperate with Hsp70/ Hsp40 and HsplOO or the GroEL/GroES chaperone networks in refolding of misfolded proteins (for a review, see (Nakamoto et al., Cell Mol Life Sci., 64:294-306, 2007). Human Hsp27 and Hsp70 are often, although not obligatorily, co-expressed in response to a variety of physiological and environmental stimuli (Garrido et al., Cell Cycle, 5:2592-2601, 2006; Vigh et al., Trends Biochem Sci., 32:357-363, 2007). As sHsps 265 have strong cytoprotective properties (Garrido et al., Cell Cycle, 5:2592-2601, 2006), their inhi bition is an important target in pharmacological therapies to cancer (Didelot et al., Curr Med Chem., 14:2839-2847, 2007), whereas the upregulation sHsps may prevent liver damage (Kanemura et al., J Gastrointest Surg., 13:66-73, 2009) or pathologies caused by protein misfold ing, such as Alzheimer's (Fonte et al., J Biol Chem 283:784-791, 2008; Wu et al., Neurobiol 270 Aging, 31:1055-1058, 2010), Parkinson's (Zourlidou et al., J Neurochem., 88:1439-1448, 2004), and Huntington's disease (Perrin et al., Mol Ther., 15(5):903-911, 2007). According to a recent study Hsp27 can protect neurons against the acute and chronic toxic effects of ethanol in trans genic mouse model (Toth et al., Cell Stress and Chaperones, 15:807-817, 2010). 275 Although Hsp modulating small compounds are known and some of them are under clinical trials none of them has been marketed as pharmaceutically active agent so far. There re mains an increasing need for specific potent Hsp modulating compounds to meet the demanding 8 WO 2013/076516 PCT/HU2012/000126 biological and pharmaceutical requirements to proceed towards human clinical trials. The ideal candidates for therapeutic use would be compounds which do not induce/silence the classical 280 heat-shock protein response per se. Instead, they only modulate the expression of specific classes of Hsps altered by mild physical or pathophysiological stresses. Such Hsp co-modulators are unique drug candidates because they may enhance/decrease HSP expression in diseased cells, without significantly affecting healthy cells thereby less likely that they have major side effects. Thus, principal aim of the present invention is the provision of compounds with selective 285 stress protein modulating activity, especially co-modulating activity, whereby they are useful in the treatment of neurodegenerative disorders, cancer diseases, metabolic syndromes, lysosomal storage diseases skin diseases and additionally could be used in combinational therapies. The present invention provides certain partly novel 1,4-dihydropyridines with selective Hsp modulating activity. It has been surprisingly and unexpectedly found that said compounds 290 show selective Hsp co-modulating activity, which has not been described for 1,4-dihydro pyridine derivatives so far. - A huge number of documents disclosed 1,4-dihydropyridine derivatives and their uses but none of them disclosed the use of the specific compounds of the present invention as Hsp modulators. 295 1,4-Dihydropyridines are particularly well known in pharmacology as L-type calcium channel blockers (Edraki et al., Drug Discovery Today, 14:1058-1066, 2009); and have been ex tensively used in the treatment of cardiovascular diseases (Hope & Lazzara, Adv Intern Med., 27:435-52, 1982). Calcium antagonist 1,4-dihydropyridines have been described for use in the treatment of neuropathies in diabetes (Taber, J. et al., US 5,438,144). The derivatives of 4-(3 300 -chlorophenyl)-5-substituted-carbamoyl-1,4-dihydropyridine-3-carboxylic acid showed selective inhibitory action of N-type calcium channel, and were effective in the treatment of acute stage of ischemic cerebrovascular disorders; progressive neurodegenerative diseases such as Alzheimer's disease, AIDS related dementia, Parkinson's disease etc. (Nakajo, A. et al., US 6,610,717). Some ester derivatives of 4-nitrophenyl-1,4-dihydropyridine-5-phosphonic acid are useful for treating 305 cancer or a pre-cancerous condition (Krouse, A.J., WO 2008/137107). Compounds with con densed 1,4-dihydropyridine skeleton have been reported to reduce elevated blood glucose level (Ono, M. et al., WO 2005/025507) or to prevent cancerous cells to divide (Mauger, J., et al., WO 2007/012972). 2,6-Unsubstituted-1,4-dihyropyridine derivatives possesses sirtuin deacetylase ac tivity and may be used for the treatment of cancer, metabolic, cardiovascular, and neurodegen 310 erative diseases (Antonello et al., J. Med. Chem., 52:5496-504, 2009). N-substituted-1,4-di hydropyridines have been reported to have coronary vasodilator and antihypertensive activity (Meyer, H. et al., HU 164867). Some N-substituted-1,4-dihydropyridine derivatives are useful in 9 WO 2013/076516 PCT/HU2012/000126 the treatment of acute and chronic ischaemic disorders by improving blood viscosity (Behner, 0., EP 0 451 654), while other N-substituted derivatives showed selective Ca 2 + dependent K+ 315 channel modulating activity and were useful for the treatment of CNS disorders (Heine, H., G., EP 0 705 819 and Heine, H., G., EP 0 717 036). SUMMARY OF THE INVENTION The invention is directed towards partly new 1,4-dihydropyridine derivatives which show 320 broad utility by exhibiting Hsp modulating activity and thereby are useful in the treatment and prevention of diseases and pathophysiological conditions mediated by Hsps. The present invention is based on the unexpected finding that the 1,4-dihydropyridine de rivatives of formula (I) - while having no or negligible effect on Ca-channels - are capable of se lectively co-modulating Hsp activity which means that they act solely by potentiating or inhibit 325 ing a pre-existing stress response and have little or no effect in non-stressed or healthy systems, they exhibit effect selectively in diseased tissue, and thereby they may reduce the risk of un wanted side effects in healthy tissue. The 1,4-dihydropyridine derivatives of formula (I), which are co-modulators may provide suitable therapeutic drug candidates for many disease states. De pending on the specific Hsp class involved the 1,4-dihydropyridine derivatives of formula (I) are 330 useful according to a non-limiting embodiment in the treatment and prevention of neurodegen erative diseases, cancer diseases, metabolic syndromes, lysosomal storage disorders or skin dis orders. As defined earlier, a stress protein co-modulator is a substance that does not affect Hsp production by itself, but can modulate Hsp induction in combination with other mild stresses which are present under different disease states. Since the compounds of invention are capable of 335 modulating the stress response in stressed cells while not affecting unstressed cells, they are unlikely to produce major side effects in contrast with many classes of current drugs. DETAILED DESCRIPTION OF THE INVENTION In one aspect the present invention provides 1,4-dihydropyridine derivatives of formula 340 (I) 0 R 1 0
    R
    5 N R 4 (I) wherein 10 WO 2013/076516 PCT/HU2012/000126 R1 is C 6
    -
    2 4 aryl group optionally substituted with one or more substituents independently selected 345 from the group consisting of halogen, straight-chained or branched Ci- 6 alkyl, haloCi 6 alkyl, Ci- 6 alkoxy, 5 to 6 membered heteroaryl comprising 1 to 4 nitrogen atoms, -CN, SO 2
    NH
    2 , C 2
    -
    6 alkenyl, C 2
    -
    6 alkynyl, C 3
    -
    8 cycloalkyl and alk-X-alk group wherein X is 0, S, SO, S02 and alk is C 1
    -
    6 alkyl; or 5 to 6 membered heteroaryl group comprising I to 3 nitro gen atoms or other heteroatoms like oxygen and sulphur, and combinations thereof; 350 R 2 and R 3 are independently hydrogen or C 1
    .
    6 alkyl group; R4 and R 5 are independently hydrogen, CI.
    6 alkyl group optionally substituted with amino, mono or di(C 1
    .
    6 alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring at tached by nitrogen and optionally comprising additional I to 3 N, 0, S heteroatoms and optionally substituted with CI 6 alkyl group or C 1
    -
    6 alkoxy group; 355 R6 is C 1
    .
    6 alkyl, C 3
    _
    7 cycloalkyl, C3.7cycloalkylC1.
    6 alkyl or arylCI.
    6 alkyl group; and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enanti omers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, sol vates, esters and prodrugs thereof for use in the therapeutic or prophylactic treatment of a disor der mediated by a heat shock protein. 360 Further aspects of the invention provide compounds of formula (I) as described above for use in the therapeutic or prophylactic treatment of a disorder mediated by Hsp70 and Hsp25, and wherein the Hsp mediated disorder is selected from the group consisting of neurodegenerative diseases, cancer diseases, metabolic syndromes, lysosomal storage diseases and skin disorders conditions, and wherein the treatment further comprises administering at least one therapeutic 365 agent selected from the group consisting of agents useful for the treatment of neurodegenerative diseases, cancer diseases, metabolic syndromes, lysosomal storage diseases or skin disorders. Another aspect of the invention provides a pharmaceutical and optionally cosmetical composition comprising a compound of formula (I) as described above and one or more pharma ceutically acceptable or cosmetically acceptable carriers and/or excipients for use in the thera 370 peutic or prophylactic treatment of a disorder mediated by a Hsp. Further aspects of the invention provide a pharmaceutical and optionally cosmetical composition comprising a compound of formula (I) as described above and one or more pharma ceutically acceptable or cosmetically acceptable carriers and/or excipients for use in the thera peutic or prophylactic treatment of a disorder mediated by a Hsp, wherein the disorders are se 375 lected from the group consisting of neurodegenerative diseases, cancer diseases, metabolic syn dromes, lysosomal storage diseases and skin disorders conditions, and wherein the treatment fur ther comprises administering at least one therapeutic agent selected from the group consisting of 11 WO 2013/076516 PCT/HU2012/000126 agents useful for the treatment of neurodegenerative diseases, cancer diseases, metabolic syn dromes, lysosomal storage diseases or skin disorders. 380 Another aspect of the invention provides a compound of formula (I) as described above for use in combination therapy wherein the combination therapy comprises administering an ef fective amount of a compound of formula (I) as described above to a patient simultaneously, separately or sequentially with a thermal treatment or with other therapies used for the treatment of the given pathophysiological state. 385 Another aspect of the invention provides certain new compounds of formula (I) as de scribed below and stereoisomers including enantiomers, diastereomers, racemic mixtures, mix ture of enantiomers and combination thereof, as well as polymorphs, pharmaceutically accept able salts, solvates, esters and prodrugs thereof in enantiomerically enriched form, furthermore pharmacological and cosmetical compositions comprising the same as well. 390 Description of Drawings Fig. 1 Hsp70 co-inducing activity of compound of Ex. 23 on SHSY5Y cells Fig. 2 Selective co-inducing activity of compound of Ex. 23 for Hsp70 over other Hsps Fig. 3 Hsp25 co-inducing activity of compound of Ex. 11 on SHSY5Y cells Fig. 4 Hsp70 silencer activity of compound Ex.27 on B16 F-10 melanoma cells Fig. 5 Fasting plasma plasma glucose level (A) and Hsp70 protein level (B) (measured with Western blot) of brown adipose tissue in Zucker obese rat treated with compound of Ex. 1 Fig. 6 Shows neuro- and memory protection by compound of Ex. 23 (PB: Physiological saline) 395 Fig. 7 Effect of compound of Ex.23 administered systemically on UVB-induced enhancement in skin thickness of SKH-l hairless mice Fig. 8 Effect of compound of Ex. 17 on the mean survival time of experimental mouse metastatic melanoma model. Fig. 9 Effect of compound of Ex. 23 on the lysosomal stability of B 16 melanoma cells 400 Fig. 10. The effect compound of Ex.23 on the lifespan of the ALS model mice The following abbreviations and definitions are used throughout the application. Abbreviations AP P-amyloid AD Alzheimer's Disease 405 APP Amyloid Precursor Protein ATPase Adenosine Triphosphatase CFTR Cystic Fibrosis Transmembrane Conductance Regulator DCIC 3,4-Dichloroisocoumarin 12 WO 2013/076516 PCT/HU2012/000126 DMEM-F12 Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 410 GFP Green Fluorescent Protein HSF Heat Shock Factor Hsp Heat Shock Protein HSR Heat Shock Response MTD Maximum Tolerated Dose 415 NEF Nucleotide Exchange Factors NFKB Nuclear Factor kappa-Light-Chain-Enhancer of Activated B Cells NFTs Neurofibrillary Tangles PB Physological Saline PBS Phosphate Buffered Saline 420 PGS Prostaglandin PPARy Peroxisome Proliferator-activated Receptor y PVDF Polyvinylidene Difluoride SDS-PAGE Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis SP Senile Plaques 425 TLCK N-a-Tosyl-L-Lysine Chloromethyl Ketone YFP Yellow Fluorescent Protein Definitions The term "Hsp modulating" refers to a process, which either increases or decreases cellu 430 lar expression, membrane association and/or function of Hsp100, Hsp90, Hsp70, Hsp60, and the "small Hsp" proteins through various mechanisms. The term "HSP co-modulating activity" refers to the action of "HSP co-modulators", which do not modulate stress response by themselves but are able to modify it in the presence of mild stress or pathophysiological conditions. Chaperone co-modulators act like "smart drugs" by 435 selective interactions with only those cells, which are under acute or chronic stress. These types of molecules may provide an important novel therapy in a number of acute and chronic diseases which either increase or decrease cellular expression, membrane association and/or function of Hsp100, Hsp90, Hsp70, Hsp60, and the "small Hsp" proteins through various mechanisms. Furthermore "modulation" refers also to changing the ratio of different Hsps. 440 The term "Hsp upregulation" refers to a process, which increases cellular expression and/or functioning of HsplOO, Hsp90, Hsp70, Hsp60, and the "small Hsp" proteins through vari ous mechanisms. 13 WO 2013/076516 PCT/HU2012/000126 The term "Hsp inducer" refers to compounds, which increase Hsp expression under a broad range of pathophysiological conditions unlike to Hsp co-inducers, which act solely to po 445 tentiate a pre-existing stress response and have little or no effect in non-stressed or healthy sys tems. The terms Hsp "chaperone co-inducer" or Hsp "co-inducer" refer to compounds, which do not induce stress response by themselves but are able to modify it in the presence of mild stress or pathophysiological conditions. Chaperone co-inducers act like "smart drugs" by selec 450 tive interactions with only those cells, which are under acute stress. These types of molecules may provide an important novel therapy in a number of acute and chronic diseases. The term "Hsp silencer" refers to a compound, which decrease Hsp expression and/or functioning under a broad range of stress including pathophysiological conditions. The term "Hsp inhibitor" refers to a compound, which is capable of demonstrating de 455 tectable inhibition of one or more Hsps. Inhibition of Hsps may be determined using the methods described and incorporated by reference herein (Wyshocka et al., Mol. Cel. Biochem. 215:153 -156, 2000). The skilled person realizes that an in vivo Hsp inhibitor is not necessarily an in vitro Hsp inhibitor, for example a prodrug form of a compound demonstrates little or no activity in in vitro 460 assays. Such prodrug forms may be altered by metabolic or other biochemical processes in the patient to provide an in vivo active compound. The term "prodrug" refers to any pharmaceutically acceptable salt, ester or other deriva tive of a compound of the invention, which upon administration to a recipient is capable of pro viding either directly or indirectly a compound of the invention or a pharmaceutically active me 465 tabolite or residue thereof. Various forms of prodrugs are well known in the art. See for example Design of Prodrugs, Bundgaard, A. Ed., Elseview, 1985 and Method in Enzymology, Widder, K. et al, Ed.; Academic, 1985, vol. 42, p. 309-396; Bundgaard, H. "Design and Application of Prod rugs" in A Textbook of Drug Design and Development, Krosgaard-Larsen and H. Bundgaard, Ed., 1991, Chapter 5, p. 113-191; and Bundgaard, H., Advanced Drug Delivery Review, 1992, 8, 470 1-38, each of which is incorporated herein by reference. The term "pathophysiological conditions" refers to any disease, disorder or effect that produces deleterious biological consequences in a subject. The pathophysiological conditions which are selectively modulated by heat shock protein activity of the compounds of invention include, but are not limited to for example 475 - neurodegenerative diseases, which are characterized by progressive nervous system dysfunc tion, in particular, Alzheimer disease, frontotemporal dementia, dementia with Lewy bodies, corticobasal degeneration, progressive supranuclear palsy, prion disorders, multiple system 14 WO 2013/076516 PCT/HU2012/000126 atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, poly-Q related neurodegenerative diseases, multiple sclerosis, heredi 480 tary spastic paraparesis, spinocerebellar atrophies, brain cancer related diseases, degenerative nerve diseases, encephalitis, epilepsy, genetic brain disorders, head and brain malformations, hydrocephalus, stroke related diseases, prion diseases, amyloidoses, Friedreich's ataxia, metabolic (diabetes) related diseases, toxin related diseases, Charcot-Marie-Tooth neuropa thy and others; 485 - cancer diseases, particularly breast cancer, small-cell lung cancer, melanoma, squamous cell carcinoma, non-small-cell lung cancer, bladder cancer, head and neck cancer, ovarian cancer, prostate cancer, Kaposi's sarcoma, glioblastoma, glioma, colorectal cancer, genitourinary cancer, gastrointestinal cancer, renal cancer, hematological cancers, cervical cancer, colon cancer, cutaneous t-cell lymphoma, esophageal cancer, liver cancer, neuroblastoma, oral 490 dysplasia, pancreatic cancer, peripheral t-cell lymphoma pheochromocytoma, sarcoma, tes ticular cancer, thyroid cancer and the like; - non-Hodgkin's lymphoma, lymphoma, multiple myeloma, leukemia (including acute mye logenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia), myelo dysplastic syndrome and mesothelioma; 495 - metabolic syndromes and related disorders caused by or manifested as increased insulin re sistance, impaired glucose tolerance, Type 2 diabetes mellitus, central obesity, elevated level of triglycerides, decreased HDL cholesterol, prothrombotic and pro-inflammatory states, polycystic ovarian syndrome (PCOS) and the like; - lysosomal storage diseases, particularly (aspartylglucosaminuria, cystinosis, Fabry disease, 500 Farber disease, fucosidosis, galactosialidosis, Gaucher disease, GMl gangliosidoses, Morquio B, GM2 gangliosidoses (0, B, AB, BI variants), Krabbe disease, metachromatic leukodystrophy (arylsulfatase A and SAPI deficient), mucolipidoses II and III (Icell disease), mucolipidosis I (Sialidosis), mucolipidosis IV, mucopolysaccharidosis I (Hurler and Scheie syndromes), mucopolysaccharidosis II (Hunter syndrome), mucopolysaccharidosis III (San 505 filippo syndrome A, B, C, D), mucopolysaccharidosis IV (Morquio syndrome A, B), muco polysaccharidosis VI (MaroteauxLamy syndrome), mucopolysaccharidosis VII (pglucuroni dase deficiency), multiple sulfatase deficiency, neuronal ceroid lipofuscinosis, Niemann-Pick disease (A,B, and C), Pompe disease, pycnodysostosis, Schindler disease, sialic acid storage disease, Wolman disease (cholesterol ester storage disease), a-mannosidosis, p-manno 510 sidosis; - skin disorders, particularly non-infectious rashes (dermatitis, psoriasis, and others), UV induced inflammations, non-cancerous skin growths (seborrheic keratoses, keratoacan 15 WO 2013/076516 PCT/HU2012/000126 thomas, keloids and others), and skin cancer (basal cell carcinoma, squamous cell carcinoma, melanoma, Kaposi's sarcoma, Paget's disease of the nipple). 515 The term "thermal therapy" also called "hyperthermia therapy" refers to medical treat ment in which body tissue is either exposed to slightly higher temperatures or body temperature is increased by the induction of fever to treat diseases and conditions, particularly cancer, in flammation, metabolic syndrome, benign prostatic hyperthropy, to reduce hemorrhoids, to stimu late the immune system, to increase the level of disease fighting white blood cells, to treat pain. 520 The term "metabolic syndrome" refers to a combination of medical conditions that, when occurring together, increase the risk of developing cardiovascular disease and diabetes. Symp toms and features include fasting hyperglycemia (Type 2 diabetes mellitus, impaired glucose tol erance, or increased insulin resistance); high blood pressure; central obesity; overweight with fat deposits; decreased HDL cholesterol; elevated triglycerides. 525 The term "subject" refers to animal, or to one or more cells derived from an animal. Pref erably, the animal is a mammal, most preferably a human. Cells may be in any form, including but not limited to cells retained in tissue, cell clusters, immortalized cells, transfected or trans formed cells, and cells derived from an animal that have been physically or phenotypically al tered. 530 The term "patient" refers to any mammal, preferably humans. A "pharmaceutically acceptable salt" may be prepared from any compound of the inven tion having functionality capable of forming salts, for example a base or acid functionality. Pharmaceutically acceptable salts may be prepared with organic or inorganic acids or bases. Compounds of the invention that contain one or more basic functional groups, (e.g., amino, al 535 kylamino), are capable of forming pharmaceutically acceptable salts with pharmaceutically ac ceptable organic and inorganic acids. These salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or by separately reacting a purified com pound of the invention in its free base form with a suitable organic or inorganic acid, and isolat ing the salt thus formed. Examples of suitable acid salts include acetate, adipate, alginate, aspar 540 tate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, gluco heptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hy drobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesul fonate, 2-napthalenesulfonate, nicotinate, nitrate, oxalate, palmoate, pectinate, persulfate, 3-phe 545 nylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, thiocyanate, tosylate and undecanoate. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates 16 WO 2013/076516 PCT/HU2012/000126 in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts. Compounds of the present invention that contain one or more acidic functional groups are 50 capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases. The term "pharmaceutically acceptable salts" in these instances refers to the relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention. These salts can likewise be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the pure compound in its free acid form with a suitable base, such as the hy 55 droxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary or tertiary amine. Representa tive pharmaceutically acceptable cations include alkali or alkaline earth salts such as lithium, so dium, potassium, calcium, magnesium, and aluminum salts and the like. Illustrative examples of some of the bases that can be used include sodium hydroxide, potassium hydroxide, choline hy 560 droxide, sodium carbonate, tetrabutylammonium hydroxid, and the like. Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethyl enediamine, ethanolamine, diethanolamine, piperazine and the like. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization. See, for ex 565 ample, Berge et al. "Pharmaceutical Salts", J. Pharm. Sci. 1977, 66:1-19. It should be understood that a reference to a salt includes the solvent addition forms or crystal forms thereof, particularly solvates or polymorphs. Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and are often formed during the process of crystalli zation with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates 570 are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Polymorphs include the different crystal packing arrangements of the same elemental composi tion of a compound. Polymorphs usually have different X-ray diffraction patterns, infrared spec tra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. Various factors such as the recrystallization solvent, rate of crystallization, and 575 storage temperature may cause a single crystal form to dominate. The term "alkyl" as used herein refers to an optionally substituted straight-chain, or op tionally substituted branched chain saturated hydrocarbon radical having from one to six car bons. Examples of alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, tert-amyl, pentyl, hexyl and the like. 580 The term "cycloalkyl" as used herein refers to cyclic alkyl monoradicals wherein each cyclic moiety has from three to seven carbon atoms. Examples of cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like. 17 WO 2013/076516 PCT/HU2012/000126 The term "alkoxy" as used herein refers to an alkyl-O- group wherein the term alkyl is defined as above. Examples of alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, 585 n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy and the like. The term "aryl" as used herein refers to an aryl group having six to ten skeletal ring car bons, for example phenyl and naphthyl. The term "arylalkyl" as used herein refers to an alkyl radical as defined above in which at least one H atom is replaced by an aryl radical as defined above, for example benzyl, 2 590 phenylethyl and the like. The term "heteroaryl" as used herein refers to aromatic groups containing five to six skeletal ring atoms where one to four of the ring atoms is a nitrogen atom or a heteroaryl group comprising 1 to 3 nitrogen atoms or other heteroatoms like oxygen and sulphur, and combina tions thereof. Examples of heteroaryl include, without limitation furanyl, thiophenyl, pyridyl, 595 pyrrolyl, pyrimidyl, pyrazinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, and the like. The term "alk-X-alk" as used herein refers to alk-O-alk, alk-S-alk, alk-SO-alk, alk-S0 2 -alk groups wherein alk is an alkyl group containing one to six carbon atoms. Examples of alk-X-alk include without limitation methoxymethyl, ethoxymethyl, methylthiomethyl, ethyl 600 thiomethyl, methylsufinylmethyl, ethylsulfinylmethyl, methylsulfonylmethy, ethylsulfonyl methyl, and the like. The term "halogen" as used herein refers to fluoro, chloro, bromo, iodo. The term "heterocyclic" as used herein refers to optionally substituted and fused, and in heterocyclic part partially saturated ring radicals containing from five to twenty four ring atoms 605 where one of the ring atoms is nitrogen and optionally the additional heteroatoms are such as for example oxygen, nitrogen, sulphur for example without limitation pirrolidinyl, piperidyl, piperazinyl, pyrrolidinyl, morpholinyl, tetrahydroisoquinolinyl, tetrahydrobenzazepinyl and the like. The said heterocyclic rings may be optionally substituted in any position with alkyl, alkoxy radicals as defined above. 610 The term "mono- or dialkylamino" as used herein refers to the groups -NHR, -NRR' where R and R' are alkyl as defined above. "Optionally substituted" groups may be substituted or not substituted. Some of the compounds of the present invention may contain one or more chiral centers and therefore may exist in enantiomeric and diastereomeric forms. The scope of the present in 615 vention is intended to cover all isomers per se, as well as mixtures of cis and trans isomers, mix tures of diastereomers and racemic mixtures of enantiomers (optical isomers) as well. 18 WO 2013/076516 PCT/HU2012/000126 Further, it is possible using well known techniques to separate the various forms, and some embodiments of the invention may feature purified or enriched species of a given enanti omer or diastereomer. 620 A "pharmacological or dermatological or cosmetical composition" refers to a mixture of one or more of the compounds described herein, or pharmaceutically acceptable salts thereof, with other chemical components, such as pharmaceutically and/or dermatologically or cosmeti cally acceptable carriers and/or excipients. The purpose of a pharmacological composition is to facilitate administration of a compound to an organism. 625 The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceuti cally acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipi ent, solvent or encapsulating material, involved in carrying or transporting the subject agent from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and 630 not injurious to the patient. Some examples of materials which can serve as pharmaceutically ac ceptable carriers include without limitation: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium car boxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed 635 oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene gly col; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hy droxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phos phate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical 640 formulations. An "excipient" refers to an inert substance added to a pharmacological composition to further facilitate administration of a compound. Examples of excipients include but are not lim ited to calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose de rivatives, gelatin, vegetable oils and polyethylene glycols. 645 A "pharmaceutically effective amount" means an amount which is capable of providing a therapeutic and/or prophylactic effect. The specific dose of compound administered according to this invention to obtain therapeutic and/or prophylactic effect will, of course, be determined by the particular circumstances surrounding the case, including, for example, the specific compound administered, the route of administration, the pathophysiological conditions being treated, and 650 the individual being treated. A typical daily dose (administered in single or divided doses) will contain a dosage level of from about 0.01 mg/kg to about 50-100 mg/kg of body weight of an ac 19 WO 2013/076516 PCT/HU2012/000126 tive compound of the invention. Preferred daily doses generally will be from about 0.05 mg/kg to about 20 mg/kg and ideally from about 0.1 mg/kg to about 10 mg/kg. Factors such as clearance rate, half-life and maximum tolerated dose (MTD) have yet to be determined but one of ordinary 555 skill in the art can determine these using standard procedures. Pharmaceutical compositions comprising a compound of formula (I) as active component may additionally comprise an agent useful for the treatment of neurodegenerative diseases, can cer diseases, metabolic syndromes, lysosomal storage diseases or skin disorders, or the pharma ceutical compositions comprising a compound of formula (I) may be co-administered with such 660 agents. The additional agent useful for the treatment of neurodegenerative diseases, cancer dis eases, metabolic syndromes, lysosomal storage diseases or skin disorders means, but not limited to antitumor agents, to agents for oral antidiabetic medications, for anti-dementia medications, for anti-Parkinson medications, for anti-multiple sclerosis medications, for anti-ALS medica 665 tions, for anti-Friedreich's ataxia medications, for anti-antiepilepsy medications, and others. Antitumour agents include, but are not limited to for example alkylating agents (cyclo phosphamide, ifosfamide, carmustine, and the like), anti-metabolites (methotrexate, raltitrexed, pemetrexed, cytarabine, fludarabine, cytarabine, fluorouracil, tegafur, gemcitabine, capecitabine, and the like), plant alkaloids and terpenoids (vinblastine, vincristine, vindesine, vinorelbine, pa 670 clitaxel, docetaxel and the like), topoisomerase inhibitors (etoposide, irinotecan, topotecan, am sacrine, etoposide phosphate, teniposide and the like, cytotoxic antibiotics (actinomycin, doxorubicin, daunorubicin, valrubicin, idarubicin, epirubicin , bleomycin, plicamycin, mitomy cin and the like), and other antitumour agents (cisplatin, carboplatin, oxaliplatin, and the like) Agents for oral anti-diabetic medications include, but are not limited to for example insu 675 lin and analogues, biguanides (metformin, buformin and the like), thiazolidinediones (rosiglita zone, pioglitazone and the like), sulfonylureas (tolbutamide, acetohexamide, tolazamide, chlor propamide, glipizide, glyburide, glimepiride, gliclazide, and the like), nonsulfonylurea secre tagogues (repaglinidine, nateglinidine and the like), alpha-glucosidase inhibitors (miglitol, acar bose and the like), incretin mimetics (exenatide, liraglutide, taspoglutide, and then like), dipepti 680 dyl peptidase-4 (DPP-4) inhibitors (vildagliptin, sitagliptin, saxagliptin, linagliptin and the like), amylin analogues (pramlintide and the like). Agents for anti-dementia medications include, but are not limited to for example donepe zil, galantamine, rivastigmine, memantime and the like. Antiparkinson medications include, but are not limited to for example biperiden, metixene, procyclidine, L-DOPA, amantadine, ropini 685 role, pramipexole, selegiline, entacapone, and the like. Anti-ALS drug (riluzole). Anti-multiple sclerosis medications include, but are not limited to for example fingolimod, interferon-beta-la 20 WO 2013/076516 PCT/HU2012/000126 and lb, glatiramer acetate, mitoxantrone, natalizumab and the like. Anti-Friedreich's ataxia medications (idebenone). Anti-antiepilepsy medications include, but are not limited to for exam ple carbamazepine, clorazepate, clonazepam, ethosuximide, felbamate, fosphenytoin , gabapen 390 tin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, pregabalin, primidone, tiagabine, topiramate, valproate semisodium, valproic acid, zonisamide, clobazam, vigabatrin and the like. Agents for treatment of lysosomal storage diseases include, but are not limited to for ex ample glycosyltransferase inhibitors, p-glucocerebrosidase, imigluderase; agalsidase alpha, agal 395 sidase beta, aglucosidase alpha, laronidase, idursulphase, galsulphase, c-glucosidase, N-butyl deoxynojirimycin, 1-deoxynojirimycin, galactose, galactostatin bisulphite, isofagomine, 2,5-an hydro-2,5-D-glucitol, N-octyl-4-epi-b-valienamine, pyrimethamine and the like. The pharmaceutical compositions of this invention may be administered orally, parenter ally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted res 700 ervoir. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques. The pharmaceutical compositions of this invention may be orally administered in any 705 orally acceptable dosage form including, but not limited to, capsules, tablets, and aqueous sus pensions and solutions. In the case of tablets for oral use, carriers which are commonly used in clude lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions and solutions and propylene glycol are administered orally, 710 the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added. Topical administration of the pharmaceutical or dermatological compositions of this in vention is especially useful when the desired treatment involves areas or organs readily accessi ble by topical application. For application topically to the skin, the pharmaceutical or derma 715 tological composition should be formulated with a suitable ointment containing the active com ponents suspended or dissolved in a carrier. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical composition can be formulated with a suitable lotion or cream 720 containing the active compound suspended or dissolved in a carrier. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl 21 WO 2013/076516 PCT/HU2012/000126 alcohol, 2-octyldodecanol, benzyl alcohol and water. The pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formu lation or in a suitable enema formulation. Topically-administered transdermal patches are also 725 included in this invention. These compositions can be prepared by methods known per se in the preparation of pharmaceutical compositions and cosmetics, by mixing the active material and the corresponding carriers and/or excipients. The compositions generally contain 0.5 to 99.5 % by weight active compound. 730 Compounds of the Invention The present invention provides partly novel 1,4-dihydropyridine derivatives of formula (1) 0 R' 0 R O O,3
    R
    5 N R 4 (I) 735 wherein R' is C 6
    -
    24 aryl group optionally substituted with one or more substituents independently selected from the group consisting of halogen, -NO 2 , straight-chained or branched
    CI-
    6 alkyl, haloCI- 6 alkyl, CI- 6 alkoxy, 5 to 6 membered heteroaryl comprising I to 4 nitro gen atoms, -CN, -SO 2
    NH
    2 , C 2
    -
    6 alkenyl, C 2
    -
    6 alkynyl, C 3
    -
    8 cycloalkyl and alk-X-alk group 740 wherein X is 0, S, SO, SO 2 and alk is C 1
    -
    6 alkyl; or 5 to 6 membered heteroaryl group comprising 1 to 3 nitrogen atoms or other heteroatoms like oxygen and sulphur, and com binations thereof;
    R
    2 and R 3 are independently hydrogen or C .
    6 alkyl group;
    R
    4 and R 5 are independently hydrogen, -CN, CI 6 alkyl group optionally substituted with amino, 745 mono- or di(C- 6 alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising additional I to 3 N, 0, S heteroa toms and optionally substituted with Ci 6 alkyl group or CI- 6 alkoxy; R6 is C 1 6 alkyl, C3.7cycloalkyl, C 3
    .
    7 cycloalkylC 1
    .
    6 alkyl or arylCI 6 alkyl group; and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enanti 750 omers and combination thereof, where appropriate, as well as polymorphs, pharmaceutically ac ceptable salts, solvates, esters and prodrugs thereof for use in the therapeutic or prophylactic treatment of a disorder mediated by a heat shock protein. 22 WO 2013/076516 PCT/HU2012/000126 In some embodiments R' is a phenyl group independently optionally substituted with one or two halogen, haloC 1
    .
    6 alkyl; R2, R 3 are independently C 1
    .
    6 alkyl group; R 4 , R5 are independ 755 ently C1.
    6 alkyl group optionally substituted with amino, mono- or di(C 1 6 alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring attached by nitrogen and optionally compris ing additional 1 to 3 N, 0, S heteroatoms and optionally substituted with C 1
    -
    6 alkyl group or
    C
    1
    .
    6 alkoxy group; R 6 is C 1
    .
    6 alkyl. In a preferred embodiment R' is a phenyl group substituted with haloC 1
    .
    6 alkyl; R2, R3 are 760 independently C 1
    .
    6 alkyl group; R 4 , R5 are independently C1salkyl group optionally substituted with mono- or di(CI- 6 alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising additional I to 3 N, 0, S heteroatoms and op tionally substituted with C 1 .salkyl group or C 1
    -
    6 alkoxy group; R6 is Ci-salkyl. In an alternative preferred embodiment R' is a phenyl group substituted with halo 765 Cs6alkyl; R2, RW are independently CIsalkyl group; R4, RW are independently CI 6 alkyl group op tionally substituted with mono- or di(Ci -6 alkyl)amino, or with 6 membered heterocyclic ring at tached by nitrogen and optionally comprising additional N heteroatom and optionally substituted with C 1
    .
    6 alkyl group; R 6 is C 1
    .
    6 alkyl. In other selected preferred embodiment R' is a phenyl group substituted with fluoro 770 -C 1
    -
    6 alkyl; R2 and R 3 are CIs-alkyl group; R4 and R5 are independently CIsalkyl group optionally substituted with di(CI.
    6 alkyl)amino, or with 5 to 12 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising one additional N heteroatom and optionally sub stituted with C 1 salkyl or C 1 salkoxy group; R 6 is C 1 -salkyl. TABLE 1: Exemplary compounds of formula (I) 0 R' 0
    R
    5 N R 4 775
    R
    6 (I) Table 1 No. R R2 R 3 R' R5 R6 1 4-F 3 C-Ph Me Me Me Me Me 2 4-F-Ph Me Me Me Me Me 3 Ph Me Me Me Me Me 4 4-Cl-Ph Me Me Me Me Me 5 4-Me-Ph Me Me Me Me Me 6 4-MeO-Ph Me Me Me Me Me 7 3-F 3 C-Ph Me Me Me Me Me 23 WO 2013/076516 PCT/HU2012/000126 No. R R 2 R 3 R 4 R 5 R6 8 2-F 3 C-Ph Me Me Me Me Me 9 3-NO2-Ph Me Me Me CN Me 10 4-(1-imidazol- Me Me Me Me Me yl)-Ph 11 4-F 3 C-Ph Me Me Me Me Et 12 4-(3-pyridyl)- Me Me Me Me Me Ph 13* 4-F 3 C-Ph Me Me Me 2-(1-pyrroli- Me dinyl)-Et 14 4-F 3 C-Ph Me Me Me 2-(Me 2 N)-Et Me 15* 4-F 3 C-Ph Me Me Me 2-(1-morpho- Me linyl)-Et 16* 4-F 3 C-Ph Me Me 2-(4-methyl-1-piperidin- 2-(4-methyl-1- Me yl)-Et piperidinyl)-Et 17* 4-F 3 C-Ph Me Me 2-(1-piperidinyl)-Et 2-(1-piperidin- Me yl)-Et 18 2-Cl-Ph Me Me Me Me Me 19* 2-Cl-Ph Me Me 2-(1-pyrrolidinyl)-Et 2-(1-pyrroli- Me dinyl)-Et 20* 2-Cl-Ph Me Me Me 2-(1-morpho- Me linyl)-Et 21* 2-Cl-Ph Me Me 2-(4-methyl-1- 2-(4-methyl-1- Me piperidinyl)-Et piperidinyl)-Et 22* 2-Cl-Ph Me Me 2-(Me 2 N)-Et 2-(Me 2 N)-Et Me 23* 4-F 3 C-Ph Me Me 2-(Me 2 N)-Et 2-(Me2N)-Et Me 24 3,5-diF-Ph Me Me Me Me Me 25* 3,5-diF-Ph Me Me 2-(Me 2 N)-Et 2-(Me 2 N)-Et Me 26* 3,5-diF-Ph Me Me Me 2-(Me 2 N)-Et Me 27 4-F 3 C-Ph Me Me Et Et Me 28 4-F 3 C-Ph Me i-Pr Me Me Me 29 4-F 3 C-Ph Me i- Me Me Me Bu 30* 4-F 3 C-Ph Me Me 2-(Me 2 N)-Et 2-(1-piperidin- Me yl)-Et 31* 4-F 3 C-Ph Me Me 2-(Me 2 N)-Et 2-(1-morpho- Me linyl)-Et 32 4-F 3 C-Ph Me Et Me Me Me 33 4-F 3 C-Ph Et Et H H c-Pr 34 4-F 3 C-Ph Et Et H H Bz 35 4-F 3 C-Ph H Me Me Me Me 36 4-F 3 C-Ph H H Me Me Me 37 4-F 3 C-Ph Et Et H H Me 38 Ph Et Et H H Bz ref. Ex 39 Ph H H H H Bz ref. Ex. 40** 4-F 3 C-Ph Me Me 2-(1,2,3,4-tetrahydroiso- Me Me quinolin-2-yl)-Et 24 WO 2013/076516 PCT/HU2012/000126 No. R1 R2 R3 R4 R 5 R 6 41* 4-F 3 C-Ph Me Me 2-(6,7-dimethoxy- Me Me 1,2,3,4-tetrahydroiso quinolin-2-yl)-Et 42* 4-F 3 C-Ph Me Me 2-(6,7-dimethoxy- 2-(Me 2 N)-Et Me 1,2,3,4-tetrahydroiso quinolin-2-yl)-Et 43** 4-F 3 C-Ph Me Me 2-(1,2,4,5-tetrahydro- Me Me bezo[d]azepin-3-yl)-Et 44 furan-2-yl Me Me Me Me Me 45 thiophen-3-yl Me Me Me Me Me 46* 4-F 3 C-Ph Me Me (pyrrolidin-1-yl)-Me Me Me 47 4-F 3 C-Ph Me Me CN Me Me 48* 4-F 3 C-Ph Me Me (piperidin-1-yl)-Me Me Me 49* 4-F 3 C-Ph Me Me (1,2,3,4-tetrahydroiso- Me Me quinolin-2-yl)-Me * HCl salt *fumarate salt 780 Selected compounds of this invention include, but are not limited to Examples 1, 4, 5, 6, 7,8,11, 12, 14, 15,16,17,23,24,25,26,27,33,34,35,41,42,43,44,45,47,49. EXAMPLES The following examples are only for the purposes of illustration of the invention and are 785 not intended to limit the spirit or the scope of the claims. Preparation of the Compounds of the Invention The compounds of formula (I) may be synthesized using conventional techniques [Hantzsch, A., "Condensationprodukte aus Aldehydammoniak und Ketonartigen Verbindungen", 790 Chemische Berichte 14 (2): 1637-1638 (1881), Jing-Jing Xia, Guan-Wu Wang "One-Pot Syn thesis and Aromatization of 1,4-Dihydropyridines in Refluxing Water", Synthesis 2005 (14): 2379-2383 (2005)]. For example compounds of the invention may be prepared using the proc esses described herein. As can be appreciated by the skilled practitioner, these processes are not the only means by which the compounds described and claimed may be synthesized. Further 795 methods will be evident to those of ordinary skill in the art. Advantageously, these compounds are conveniently synthesized from commercially available starting materials. Otherwise their preparation is referenced or described.herein. Compounds of the invention are characterized by 'HNMR data (recorded in deuteriated solvents on a 400 MHz Bruker spectrometer) and/or melting points. 800 General procedures 25 WO 2013/076516 PCT/HU2012/000126 Procedure A A mixture of 0.05 mol of aldehyde, 0.1 mol of methyl acetoacetate (or the corresponding ketoester), 0.05 mol methylamine-hydrochloride (or other alkylamine salt) was refluxed in 25 ml 805 pyridine for 5 hours. After evaporation of the solvent the residue was dissolved in dichloro methane, washed with water. The organic phase was dried and evaporated. The residue was crys tallized from methanol Procedure B 810 1 mmol of dihydropyridine, 2 mmol of dimethylamine-hydrochloride (or other amine), 2 mmol of paraformaldehyde and 1 ml acetic acid were mixed and heated on 95'C for I hour. The mixture was evaporated, dissolved in water and extracted with ether. After separation the aque ous phase was neutralised and extracted with ethyl acetate. The organic phase was dried and evaporated and the residue was purified by column chromatography on A1 2 0 3 with s mixture of 815 hexane/ethyl acetate. The pure fractions were collected, transferred to hydrochloride salts and re crystallized from methanol-diethyl ether. Procedure C 1 mmol of dihydropyridine, 5 mmol of dimethylamine-hydrochloride (or other amine), 5 820 mmol of paraformaldehyde and 1 ml acetic acid were mixed and heated on 95'C for 5 hours. The mixture was evaporated, dissolved in water and extracted with ether. After separation the aque ous phase was neutralised with NaHCO 3 and extracted with ethyl acetate. The organic phase was dried and evaporated and the residue was purified by column chromatography on silica with s mixture of hexane/ethyl acetate. The pure fractions were collected, transferred to hydrochloride 825 or to other salts and recrystallized from methanol diethyl ether. Procedure D 5 mmol of aldehyde, 5 mmol of methyl 3-aminocrotonate and 5 mmol of isopropyl (ethyl or tert-butyl) acetoacetate were dissolved in methanol and refluxed for 16 hours. After 830 evaporation the residue was dissolved in 20 ml mol of tetrahydrofurane and a suspension of 2 equivalent in NaH in 10 ml THF was carefully added and stirred at room temperature for 3 hours. Then 2 equivalent of methyl iodide was added. After 2 hours the product was carefully decomposed with methanol. The product was dissolved in water and extracted with ethyl acetate. The organic phase was dried and evaporated. The organic phase was dried and evaporated and 835 the residue was purified by column chromatography on silica with s mixture of hexane/ethyl ace tate. The pure fractions were collected, and recrystallized from hexane. 26 WO 2013/076516 PCT/HU2012/000126 Procedure E A mixture of 1 mmol dihydropyridine, 5N KOH (5 ekv.) and 10 ml ethanol was stirred at 40 80'C-on for 8 hours. After evaporation the residue was dissolved in 25 ml water and acidified with 2N of HCl. The crystalline product was filtered off and was purified by column chromatog raphy on A1 2 0 3 with s mixture of toluene/methanol. The pure fractions were collected recrystal lized from diisopropyl ether-methanol. 45 Procedure F A mixture of 1 mmol dihydropyridine, 5N KOH (10 ekv.) and 10 ml ethanol was stirred at 80'C-on for 2 days. After evaporation the residue was dissolved in 25 ml water and acidified with 2N of HCl. The crystalline product was filtered off, washed with water and recrystallized from a mixture of methanol and acetonitrile. 50 Procedure G 1 mmol of Dimethyl 2-(2-dimethylaminoethyl)-1,6-dimethyl-4-(4-trifluoromethyl -phenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride (or a corresponding dihydropyri dine derivative), 5 mmol of the corresponding secondary amine 5 mmol of paraformaldehyde 55 and 1 ml acetic acid were mixed and heated on 95'C for 1 hour. The mixture was evaporated, dissolved in water and extracted with ether. After separation the aqueous phase was neutralised and extracted with ethyl acetate. The organic phase was dried and evaporated and the residue was purified by column chromatography on A1 2 0 3 with s mixture of hexane/ethyl acetate. The pure fractions were collected, transferred to hydrochloride salts and recrystallized from methanol 360 diethyl ether. Procedure H 6 mmol of ethyl propiolate, 3 mmol of aldehyde and 3 mmol of the corresponding amine were dissolved in 0.2 ml acetic acid. The mixture was heated at 80'C for 3 hours. After cooling it 365 was mixed with water and extracted with ethyl acetate, dried and evaporated. The residue was crystallized from n-hexane. Procedure I The corresponding 2- methyl dihydropyridine derivative was transformed to 2 B70 bromomethyl derivative in pyridine with pyridiniumbromoperbromide ((ref. Chem. Pharm. Bull. 27 WO 2013/076516 PCT/HU2012/000126 45, 1997, 869). 1 mmol of this product was solved in 10 ml acetonitrile and 2 eq. of K 2 C0 3 and 1.2 eq. of the corresponding amine was added. The mixture was stirred till the reaction was com pleted, filtered and evaporated and the residue was chromatographed. B75 Procedure J The corresponding 2- methyl dihydropyridine derivative was transformed to 2-formyl derivative in DMSO in the presence of NaHCO3 ((ref. Chem. Pharm. Bull. 45, 1997, 869). 1 mmol of this product was solved in acetic acid and one eq. of hydroxylamine HCl and 1.5 eq of NaOAc was added. After one hour stirring 4 mmol of acetic anhydride was added and the mix 880 ture was refluxed for 3 hours. After evaporation the residue was neutralized and the 2-cyano de rivative was extracted with ethyl acetate, and purified after drying and evaporation by column chromatography. Table 2: Physical data of compounds of formula (I) Structure Ex. Chemical Name Mp. General No. (*C) Method
    CF
    3 Dimethyl 1,2,6 trimethyl-4-(4
    H
    3 COOC COOCH, 1 trifluoromethylphenyl)- 159-160 A 1,4-dihydropyridine
    H
    3 C N CH 3 3,5-dicarboxylate
    CH
    3 F Dimethyl 1,2,6 trimethyl-4-(4
    H
    3 COOC COOCH 3 2 fluorophenyl)-1,4- 184-185 A I dihydropyridine-3,5
    H
    3 C N CH 3 dicarboxylate
    CH
    3 Dimethyl 1,2,6
    H
    3 COOC COOCH 3 3 trimethyl-4-phenyl-1,4- 201-203 A I dihydropyridine-3,5
    H
    3 C N CH 3 dicarboxylate
    CH
    3 CI Dimethyl 1,2,6 trimethyl-4-(4 H3COOC COOCH 3 4 chlorophenyl)-1,4- 179-180 A I I dihydropyridine-3,5
    H
    3 C N CH 3 dicarboxylate
    CH
    3 28 WO 2013/076516 PCT/HU2012/000126 Structure Ex. Chemical Name Mp. General No. "C) Method
    CH
    3 Dimethyl 1,2,6 trimethyl-4-(4
    H
    3 COOC COOCH 3 5 methylphenyl)-1,4- 176-178 A dihydropyridine-3,5
    H
    3 C N CH 3 dicarboxylate
    OH
    3
    OCH
    3 Dimethyl 1,2,6 trimethyl-4-(4
    H
    3 COOC COOCH 3 6 methoxyphenyl)-1,4- 163-164 A dihydropyridine-3,5
    H
    3 C N CH 3 dicarboxylate
    CH
    3
    CF
    3 Dimethyl 1,2,6
    H
    3 COOC COOCH 3 7 trimethyl-4-(3- 118-119 A I trifluoromethyiphenyl)
    H
    3 C N CH 3 1,4-dihydropyridine
    OH
    3 3,5-dicarboxylate
    CF
    3 Dimethyl 1,2,6
    H
    3 COOC COOCH3 8 trimethyl-4-(2- 168-170 A Nc COOCH 3 8 trifluoromethylphenyl)
    H
    3 CN CH 3 1,4-dihydropyridine
    OH
    3 3,5-dicarboxylate
    NO
    2 Dimethyl 2-cyano-1,6 dimethyl-4-(3
    H
    3 COOC COOCH3 9 nitrophenyl)-1,4- 150-151 J dihydropyridine-3,5 NC N CH 3 dicarboxylate
    CH
    3 Dimethyl 1,2,6 N trimethyl-4-(4-(1 -imid azoly)lphenyl)-1,4 10 dihydropyridine-3,5- 201-202 A 10C COOCH3dicarboxylate
    H
    3 COOC COOCH 3 I |
    H
    3 C N CH 3
    OH
    3 29 WO 2013/076516 PCT/HU2012/000126 Structure Ex. Chemical Name Mp. General No. (OC) Method
    CF
    3 Dimethyl 1-ethyl-2,6 dimethyl-4-(4 trifluoromethylphenyl)
    H
    3 COOC COOCH 3 11 1,4-dihydropyridine- 135-137 A 3,5-dicarboxylate
    H
    3 C N CH 3 KCH3 N Dimethyl 1,2,6 trimethyl-4-(3-piridyl)
    H
    3 COOC COOCH 3 12 1,4-dihydropyridine- 173-175 A I 3,5-dicarboxylate
    H
    3 C N CH 3
    CH
    3
    CF
    3 Dimethyl 6-(2 pyrrolidin- 1 -yl-ethyl) 1,2-dimethyl-4-(4 13 trifluoromethyl- 218-219 B
    H
    3 COOC
    COOCH
    3 phenyl)- 1,4
    H
    3 C N dihydropyridine-3,5
    CH
    3 HCI dicarboxylate hydro chloride
    CF
    3 Dimethyl 2-(2 dimethylaminoethyl) 1,6-dimethyl-4-(4 14 trifluoromethyl- 214-216 B
    H
    3 COOC
    COOCH
    3 phenyl)-1,4
    H
    3 C N N-CH3 dihydropyridine-3,5 CH HCI CH3 dicarboxylate hydro chloride
    CF
    3 Dimethyl 1,2-dimethyl 6-(2-morpholin-4-yl ethyl)-4-(4-trifluoro
    H
    3 COOC COOCH 3 15 methyl-phenyl)-1,4- 188-193 B I I dihydropyridine-3,5
    H
    3 C N HCl N_ dicarboxylate hydro
    CH
    3 CI 0 chloride CF, Dimethyl 1-methyl-2,6 bis-[2-(4-methyl piperazin-1-yl)-ethyl]
    H
    3 COOC COOCH 3 16 4-(4-trifluoromethyl- 195-200 C I N Nphenyl)-1,4 N 6H3 N, dihydropyridine-3,5
    H
    3 C -4 HCI CH 3 dicarboxylate hydro chloride 30 WO 2013/076516 PCT/HU2012/000126 Structure Ex. Chemical Name Mp. General No. (*C) Method
    CF
    3 Dimethyl 1-methyl-2,6 bis-(2-piperidin- 1-yl
    H
    3 COOC COOCH 3 17 ethyl)-4-(4- 208-210 C I trifluoromethylphenyl) NON N 1,4-dihydropyridine ND CH 3 3,5-dicarboxylate dihy -2 HCI drochloride C1 Dimethyl 4-(2
    H
    3 COOC COOCH 3 18 chlorophenyl)-1,2,6- 154-155 A trimethyl-1,4
    H
    3 C N CH 3 dihydropyridine-3,5
    CH
    3 dicarboxylate N Dimethyl 4-(2 C1 chlorophenyl)- 1
    H
    3 COOC COOCH 3 methyl-2,6-bis-(2 | I 19 pyrrolidin-1-yl-ethyl)- 188-193 C N N N 1,4-dihydropyridine CH3 3,5-dicarboxylate dihy 2 HCI drochloride Dimethyl 4-(2 H0 chlorophenyl)-1,2 C 20 dimethyl-6-(2
    HCOOCCOCH
    3 20 morpholin-4-ethyl)- 1,4- 171-173 B
    H
    3 C N N dihydropyridine-3,5
    OH
    3 CH C O dicarboxylate hydro chloride Dimethyl 4-(2 chlorophenyl)-1I
    H
    3 COOC OOCH 3 methyl-2,6-bis-[2-(4 I I 21 methyl-piperazin-1-yl)- 210-215 C NN N ethyl]-1,4
    H
    3 C'N_ C 3 N'CH3 dihydropyridine-3,5 4 HCI dicarboxylate tetrahy drochloride Dimethyl 4-(2 CI chorophenyl)-2,6-bis
    H
    3 COOC COOCH 3 (2-dimethylamino S H3 22 ethyl)-1-methyl-1,4- 241-245 C 3CN N NCH3 dihydropyridine-3,5 I I I
    CH
    3
    CH
    3
    CH
    3 dicarboxylate dihydro 2 HCI chloride 31 WO 2013/076516 PCT/HU2012/000126 Structure Ex. Chemical Name Mp. General No. (OC) Method
    CF
    3 Dimethyl 4-(4 trifuoromethylphenyl) 2,6-bis-(2
    H
    3 COOC COOCH 3 23 dimethylaminoethyl)-1- 273-276 C I Imethyl-1,4 H3C N NH3 dihydropyridine-3,5
    CH
    3
    CH
    3
    CH
    3 dicarboxylate dihydro 2 HCI chloride F F Dimethyl 4-(3,5 difluorophenyl)- 1,2,6
    H
    3 COOC COOCH 3 24 trimethyl-1,4- 167-168 A I dihydropyridine-3,5
    H
    3 C N CH 3 dicarboxylate
    CH
    3 F F Dimethyl 4-(3,5 Difluorophenyl)-2,6
    H
    3 COOC
    COOCH
    3 bis-(2-dimethylamino 25 ethyl)-1-methyl-1,4- 261-265 C
    H
    3 -N N N'CH 3 dihydropyridine-3,5
    OH
    3
    OH
    3 OH, dicarboxylate dihydro 2 HCI chloride F F Dimethyl 4-(3,5 difluorophenyl)-2-(2 dimethylamino-ethyl)
    H
    3 COOC COOCH 3 26 1,6-dimethyl-1,4- 201-203 B
    H
    3 C N N-CH3 dihydropyridine-3,5
    OH
    3 -OHC 6H 3 dicarboxylate hydro chloride
    CF
    3 Dimethyl 2,6-diethyl-1 methyl-4 (triflouromethyl H3COOC COOCH3 27 phenyl)-1,4- 136-138 A
    H
    3 0 0H 3 dihydropyridine-3,5 H3C dicarboxylate
    OH
    3 1,2,6-Trimethyl-4-(4
    CF
    3 trifluoromethyl phenyl)-1,4 0 CH dihydropyridine-3,5
    H
    3 COOC 28 dicarboxylic acid 3- 92-94 D 0OCH 3 isopropyl ester 5
    H
    3 C N CH 3 methyl ester
    CH
    3 32 WO 2013/076516 PCT/HU2012/000126 Structure Ex. Chemical Name Mp. General No. (OC) Method
    CF
    3 1,2,6-Trimethyl-4-(4 trifluoromethyl o H C phenyl)-1,4 H3COOC 3 CH3 29 dihydropyridine-3,5- 128-130 D ||0 CH3 dicarboxylic acid 3-tert H3C N CH 3 butyl ester 5-methyl es
    OH
    3 ter
    CF
    3 Dimethyl 2-(2 dimethylamino-ethyl) 1 -methyl-6-(2 piperidin- 1 -yl-ethyl)-4
    H
    3 COOC COOCH 3 30 (4-trifluoromethyl- 247-249 E H3C'N N N phenyl)-1,4-dihydro
    OH
    3
    CH
    3 pyridine-3,5 2 HO dicarboxylate dihydro chloride CF, Dimethyl 2-(2 dimethylamino-ethyl) 1 -methyl-6-(2 morpholin- 1 -yl-ethyl)
    H
    3 COOC COOCH 3 31 4-(4-trifluoromethyl- 247-248 E H3C'N N N phenyl)-1,4-dihydro
    CH
    3
    CH
    3 1O pyridine-3,5 -2 HCI dicarboxylate dihydro chloride
    CF
    3 1,3,6-Trimethyl-4-(4 trifluoromethyl phenyl)-1,4
    H
    3 COOC COOC 2 H, 32 dihydropyridine-3,5- 146-149 D I dicarboxylic acid 3
    H
    3 C N CH 3 ethyl ester 5-methyl es
    CH
    3 ter
    CF
    3 Diethyl 1 -cyclopropyl 4-(4 C2HOOC COOC2H5 33 trifluoromethylphenyl)- 123-124 H 1,4-dihydro-pyridine N 3,5-dicarboxylate
    CF
    3 Dimethyl 1-benzyl-4 (4-trifluoromethyl
    C
    2
    H
    5 OOC COOC 2
    H
    5 34 phenyl)-1,4-dihydro- 107-108 H pyridine-3,5 N dicarboxylate 33 WO 2013/076516 PCT/HU2012/000126 Structure Ex. Chemical Name Mp. General No. (*C) Method
    CF
    3 1,2,6-Trimethyl-4-(4 trifluoromethyl HOOC COOCH 3 35 phenyl)-1,4- 150-155 E I I dihydropyridine-3,5
    H
    3 C N CH 3 dicarboxylic acid
    CH
    3 monomethyl ester
    CF
    3 1,2,6-Trimethyl-4-(4 trifluoromethyl HOOC COOH 36 phenyl)-1,4- 152-153 F I dihydropyridine-3,5
    H
    3 C N CH 3 dicarboxylic acid
    OH
    3 CF, Diethyl 1 -methyl-4-(4 trifluoromethylphenyl)
    C
    2 HOOC COOC2H, 37 1,4-dihydropyridine- 94-96 H I I 3,5-dicarboxylate N
    CH
    3 38 Diethyl 1-benzyl-4
    C
    2 HOOC COOC 2 H, phenyl- 1,4 Ref. dihydropyridine-3,5- 154-156 H N dicarboxylate Ex.
    1 -Benzyl-4-phenyl- 1,4 HOOC COOH dihydropyridine-3,5 Ref. dicarboxylic acid 204-206 F N Ex. CF, Dimethyl 2-[2-(1,2,3,4 tetrahidroisoquinolin-2 HOOC yl)-ethyl]-1,6-dimethyl
    CH
    3 00C COOCH 3 40 4-(4-trifluoromethyl- 186-188 C I COOH phenyl)-1,4
    H
    3 C N N dihydropyridine-3,5
    CH
    3 dicarboxylate fumarate 34 WO 2013/076516 PCT/HU2012/000126 Structure Ex. Chemical Name Mp. General No. (*C) Method CF3 Dimethyl 2-[2-(6,7 dimethoxy- 1,2,3,4 tetrahydroisoquinolin 2-yl)-ethyl]-1,6
    CH
    3 00C COOCH 3 41 dimethyl-4-(4- 176-81 C OCH3 trifluoromethylphenyl)
    H
    3 C N N 1,4-dihydropyridine . HCI OCH 3 3,5-dicarboxylate hydrochloride Dimethyl 2-[2-(6,7
    CF
    3 dimethoxy-1,2,3,4 tetrahydroisoquinolin 2-yl)-ethyl]-6-(2
    CH
    3 00C COOCH 3 42 dimethylamino-ethyl)- 210-211 G H3C, OCH I -methyl-4-(4 N N N trifluoromethylphenyl) CH. CH, .2 HCI OCH 3 1,4-dihydropyridine 3,5-dicarboxylate dihydrochloride CF, Dimethyl 1,2-dimethyl 6-[2-(1,2,4,5 HOOC tetrahydro COOC Ibenzo[d]azepin-3-yl) C COOH ethyl]-4-(4- 202-203 C trifluoromethylphenyl) HIC N N 1,4-dihydropyridine
    CH
    3 / 3,5-dicarboxylate fumarate 0 Dimethyl 4-(furan-2-yl
    CH
    3 00C COOCH, 44 1,2,6-trimethyl-1,4- 142-143 A I ( dihydropyridine-3,5
    H
    3 C N CH, dicarboxylate
    CH
    3 /s Dimethyl 1,2,6
    CH
    3 00C COOCH 3 45 Trimethyl-4-(thiophen- 187-189 A 3-yl)-1,4
    H
    3 C N CH 3 dihydropyridine-3,5
    CH
    3 dicarboxylate
    CF
    3 Dimethyl 1,2-dimethyl 6-pyrrolidin-1 ylmethyl-4-(4 CH300C COOCH3 46 trifluoromethylphenyl)- 182-185 I 1,4-dihydropyridine HC N N 3,5-dicarboxylate
    CH
    3 . HCI hydrochloride 35 WO 2013/076516 PCT/HU2012/000126 Structure Ex. Chemical Name Mp. General No. (*C Method
    CF
    3 Dimethyl 2-cyano-1,6 dimethyl-4-(4 CH300C COOCH, 47 trifluoromethylphenyl)- 129-132 J I IO 1,4-dihydropyridine H3C N CN 3,5-dicarboxylate
    CH
    3
    CF
    3 Dimethyl 1,2-dimethyl 6-piperidin- I -ylmethyl 4-(4-trifluoro CH3OOC COOCH3 48 methylphenyl)-1,4- 190-192 1 1 OH dihydropyridine-3,5 HC N N dicarboxylate CI . HCI hydrochloride CF, Dimethyl 2-(1,2,3,4 tetrahydro-1H isoquinolin-2 ylmethyl)-1,6-dimethyl
    CH
    3 00C COOCH 3 - 4-(4-trifluoromethyl- 175-177 phenyl)-1,4
    H
    3 C N N dihydropyridine-3,5
    CH
    3 HCI dicarboxylate hydrochloride
    CF
    3 Dimethyl 2-cyano-1 methyl-6-pyrrolidin-1 ylmethyl-4-(4
    H
    3 COOC COOCH 3 50 trifluoromethylphenyl)- 173-175 I N N I m) 1,4-dihydropyridine NC N NI 3,5-dicarboxylate
    CH
    3 HCI hydrochloride
    CF
    3 Dimethyl 2-cyano-6-(2 dimethylaminoethyl)- 1 methyl-4-(4
    H
    3 COOC COOCH 3 51 trifluoromethylphenyl)- 215-216 C | I 1,4-dihydropyridine NC N'CH3 3,5-dicarboxylate
    CH
    3
    H
    3 C HCI hydrochloride 885 'HNMR data of the compounds synthesized: Example 1: CDC1 3 , 400MHz, 6: 7.45 (d, J=8.0 Hz, 2H, ArH), 7.29 (d, J=8.0 Hz, 2H, ArH), 5.24 (s, 1H, CH), 3.75 (s, 6H, COOCH 3 ), 3.22 (s, 3H, N-CH 3 ), 2.52 (s, 6H, CH 3 ). Example 2: CDC 3 , 400MHz, 8: 7.06-7.12 (m, 2H, ArH), 6.84-6.91 (m, 2H, ArH), 5.11 (s, 1H, 890 CH), 3.71 (s, 6H, COOCH 3 ), 3.18 (s, 3H, N-CH 3 ), 2.47 (s, 6H, CH 3 ). 36 WO 2013/076516 PCT/HU2012/000126 Example 3: CDCl 3 , 400MHz, 6: 7.17-7.22 (m, 2H, ArH), 7.10-7.15 (m, 3H, ArH), 5.16 (s, 1H, CH), 3.71 (s, 6H, COOCH 3 ), 3.17 (s, 3H, N-CH 3 ), 2.48 (s, 6H, CH 3 ). Example 4: CDC1 3 , 400MHz, 8: 7.13-7.18 (m, 2H, ArH), 7.04-7.09 (m, 2H, ArH), 5.11 (s, 1H, CH), 3.70 (s, 6H, COOCH 3 ), 3.17 (s, 3H, N-CH 3 ), 2.47 (s, 6H, CH 3 ). 95 Example 5: CDC1 3 , 400MHz, 6: 6.97-7.08 (m, 4H, ArH), 5.11 (s, 1H, CH), 3.70 (s, 6H,
    COOCH
    3 ), 3.17 (s, 3H, N-CH 3 ), 2.47 (s, 6H, CH 3 ), 2.27 (s, 3H, Ar-CH 3 ), Example 6: CDCl 3 , 400MHz, 6: 7.06 (d, J=8.8 Hz, 2H, ArH), 6.74 (d, J=8.8 Hz, 2H, ArH), 5.08 (s, IH, CH), 3.75 (s, 3H, O-CH 3 ), 3.70 (s, 6H, COOCH 3 ), 3.17 (s, 3H, N-CH 3 ), 2.47 (s, 6H,
    CH
    3 ). 00 Example 7: CDC1 3 , 400MHz, 6: 7.31-7.45 (m, 4H, ArH), 5.23 (s, IH, CH), 3.75 (s, 6H,
    COOCH
    3 ), 3.22 (s, 3H, N-CH 3 ), 2.53 (s, 6H, CH 3 ). Example 8: CDC1 3 , 400MHz, 6: 7.18-7.54 (m, 4H, ArH), 5.53 (s, 1H, CH), 3.64 (s, 6H,
    COOCH
    3 ), 3.26 (s, 3H, N-CH 3 ), 2.32-2.43 (m, 6H, CH 3 ). Example 10: CDC 3 , 400MHz, 8: 7.79 (s, IH, ArH), 7.19-7.33 (m, 6H, ArH), 5.19 (s, IH, CH), 05 3.73 (s, 6H, COOCH 3 ), 3.21 (s, 3H, N-CH 3 ), 2.50 (s, 6H, CH 3 ). Example 11: CDC1 3 , 400MHz, 6: 7.49 (d, J=8.3 Hz, 2H, ArH), 7.33 (d, J=8.3 Hz, 2H, ArH), 5.20 (s, IH, CH), 3.75 (s, 6H, COOCH 3 ), 3.73 (t, J=7.0 Hz, 2H, -CI-CH 3 ), 2.52 (s, 6H, CH 3 ), 1.08 (t, J=7.0 Hz, 3H, -CH 2
    -CH
    3 ). Example 12: CDC1 3 , 400MHz, 6: 8.36-8.43 (m, IH, ArH), 7.43-7.49 (m, 1H, ArH), 7.10-7.17 '10 (m, I H, ArH), 5.13 (s, I H, CH), 3.71 (s, 6H, COOCH 3 ), 3.20 (s, 3H, N-CH 3 ), 2.49 (s, 6H, CH 3 ). Example 13: D 2 0, 400 MHz, 6: 7.68 (d, J=8.0 Hz, 2H, ArH), 7.45 (d, J=8.0 Hz, 2H, ArH), 5.19 (s, 1H, CH), 3.83 (s, 3H, COOCH 3 ), 3.80 (s, 3H, COOCH 3 ), 3.53-3.58 (m, 8H, -CH 2 -), 3.34 (s, 3H, N-CH 3 ), 2.51 (s, 3H, CH 3 ), 2.16 (s, 4H, -CH 2 -). Example 14: D 2 0, 400 MHz, 6: 7.62 (d, J=8.6 Hz, 2H, ArH), 7.40 (d, J=8.6 Hz, 2H, ArH), 5.14 15 (s, IH, CH), 3.79 (s, 3H, COOCH 3 ), 3.75 (s, 3H, COOCH 3 ), 3.30-3.61 (m, 4H, -CH 2 -), 3.29 (s, 3H, N-CH 3 ), 2.98 (s, 6H, N(-CH 3
    )
    2 ), 2.47 (s, 3H, CH 3 ). Example 15: D 2 0, 400 MHz, 5: 7.69 (d, J=8.6 Hz, 2H, ArH), 7.44 (d, J=8.6 Hz, 2H, ArH), 5.24 (s, 1H, CH), 3.87-4.30 (m, 8H, -CH 2 -), 3.84 (s, 6H, COOCH 3 ), 3.29-3.69 (m, 10H, -CH 3 , -CH 2 -). Example 16: D 2 0, 400 MHz, 6: 7.41-7,89 (m, 4H, ArH), 5.18 (s, IH, CH), 2.27-3.92 (m, 39H, )20 CH 3 , -CH 2 -). Example 17: D 2 0, 400 MHz, 6: 7.68 (d, J=8.6 Hz, 2H, ArH), 7.44 (d, J=8.6 Hz, 2H, ArH), 5.23 (s, 1H, CH), 3.63 (s, 6H, COOCH 3 ), 3.00-3.91 (m, 20H, -CH 3 , -CH 2 -), 1.40-2.15 (m, I IH, -CH 3 ,
    -CH
    2 -). Example 18: CDCl 3 , 400MHz, 6: 7.04-7.31 (m, 4H, ArH), 5.53 (s, IH, CH), 3.70 (s, 6H, )25 COOCH 3 ), 3.27 (s, 3H, N-CH 3 ), 2.47 (s, 6H, CH 3 ). 37 WO 2013/076516 PCT/HU2012/000126 Example 19: D 2 0, 400 MHz, 6: 7.46-7.52 (m, 1H, ArH), 7.19-7.35 (m, 3H, ArH), 5.48 (s, 1H, CH), 3.70-3.81 (m, 1OH, COOCH 3 , -CH 2 -), 3.10-3.52 (m, 15H, -CH 3 , -CH 2 -), 2.00-2.30 (m, 8H,
    -CH
    2 -). Example 20:D 2 0, 400 MHz, 8: 7.46-7.53 (m, 1H, ArH), 7.19-7.35 (m, 3H, ArH), 5.48 (s, 1H, )30 CH), 3.20-4.32 (m, 24H, -CH 3 , -CH 2 -). Example 21: D 2 0, 400 MHz, 5: 7.47-7.53 (m, 1H, ArH), 7.19-7.35 (m, 3H, ArH), 5.48 (s, 1H, CH), 3.03-3.84 (m, 39H, -CH 3 , -CH 2 -). Example 22: D 2 0, 400 MHz, 5: 7.47-7.53 (m, 1H, ArH), 7.37-7.27 (m, 2H, ArH), 7.19-7.24 (m, 1H, ArH), 5.48 (s, IH, CH), 3.80 (s, 6H, COOCH 3 ) 3.28-3.49 (m, I IH, -CH 2 -, -CH 3 ) 3.02 (s, )35 12H, -CH 3 ). Example 23: D 2 0, 400 MHz, 8: 7.51 (d, J=8.3 Hz, 2H, ArH), 7.28 (d, J=8.6 Hz, 2H, ArH), 5.07 (s, 1H, CH), 3.67 (s, 6H, COOCH 3 ), 3.14-3.59 (m, 11H, -CH 2 -, -CH 3 ), 2.87 (s, 12H, -CH 3 ). Example 24: CDC1 3 , 400MHz, 5: 6.64-6.73 (m, 2H, ArH), 6.55-6.63 (m, 1H, ArH), 5.17 (s, 1H, CH), 3.75 (s, 6H, COOCH 3 ), 3.21 (s, 3H, N-CH 3 ), 2.52 (s, 6H, CH 3 ). 340 Example 25: D 2 0, 400 MHz, 8: 6.71-6.82 (m, 3H, ArH), 5.07 (s, 1H, CH), 3.73 (s, 6H,
    COOCH
    3 ), 3.16-3.39 (m, 11H, -CH 2 -, -CH 3 ), 2.92 (s, 12H, -CH 3 ). Example 26: D 2 0, 400 MHz, 5: 6.76-6.86 (m, 3H, ArH), 5.07 (s, 1H, CH), 3.78 (s, 3H,
    COOCH
    3 ), 3.75 (s, 3H, COOCH 3 ), 3.23-3.37 (m, 7H, -CH 2 -, -CH 3 ), 2.97 (s, 6H, -CH 3 ), 2.46 (s, 3H, -CH 3 ). 945 Example 27: CDC1 3 , 400MHz, 5: 7.39 (d, J=8.6 Hz, 2H, ArH), 7.21 (d, J=8.6 Hz, 2H, ArH), 5.08 (s, IH, CH), 3.67 (s, 6H, COOCH 3 ), 3.14 (s, 3H, N-CH 3 ), 2.99-3.11 (m, 2H, -CH 2 -), 2.71 2.84 (m, 2H, -CH 2 -), 1.06-1.12 (m, 6H, CH 3 ). Example 28: CDC1 3 , 400MHz, 5: 7.45 (d, J=8.6 Hz, 2H, ArH), 7.28 (d, J=8.6 Hz, 2H, ArH), 5.18 (s, 1H, CH), 5.01-5.09 (m, 1H, CH), 3.71 (s, 3H, COOCH 3 ), 3.19 (s, 3H, N-CH 3 ), 2.44-2.53 950 (m, 6H, -CH 3 ), 1.18-1.33 (m, 6H, CH 3 ). Example 29: CDC1 3 , 400MHz, 8: 7.45 (d, J=8.6 Hz, 2H, ArH), 7.28 (d, J=8.6 Hz, 2H, ArH), 5.18 (s, I H, CH), 3.73 (s, 3H, COOCH 3 ), 3.20 (s, 3H, N-CH 3 ), 2.52 (s, 3H, CH 3 ), 2.45 (s, 3H,
    CH
    3 ), 1.50 (s, 9H, CH 3 ). Example 30: D 2 0, 400 MHz, 5: 7.71 (d, J=8.6 Hz, 2H, ArH), 7.46 (d, J=8.6 Hz, 2H, ArH), 5.26 955 (s, 1H, CH), 3.86 (s, 6H, COOCH 3 ), 2.85-3.76 (m, 21H, -CH 2 -, -CH 3 ), 1.39-2.17 (m, 6H, -CH 3 ). Example 31: D 2 0, 400 MHz, 5: 7.67 (d, J=8.6 Hz, 2H, ArH), 7.43 (d, J=8.6 Hz, 2H, ArH), 5.22 (s, IH, CH), 2.93-4.14 (m, 28H, COOCH 3 , -CH 2 -, -CH 3 ). Example 32: CDCl 3 , 400MHz, 5: 7.49 (d, J=8.6 Hz, 2H, ArH), 7.33 (d, J=8.6 Hz, 2H, ArH), 5.26 (s, 1H, CH), 4.16-4.25 (m, 2H, -CH 2 -), 3.23 (s, 3H, N-CH 3 ), 2.54 (s, 6H, CH 3 ), 1.24-1.34 960 (m, 3H, -CH 3 ). 38 WO 2013/076516 PCT/HU2012/000126 Example 33: CDC1 3 , 400MHz, 5: 7.52 (d, J=8.6 Hz, 2H, ArH), 7.36 (d, J=8.6 Hz, 4H, ArH, CH-), 4.98(s, 1H, CH), 4.03-4.20 (m, 4H, -CH 2 -), 3.01-3.08 (m, 1H, -CH-) 1.18-1.26 (m, 6H,
    CH
    3 ), 0.85-1.01 (m, 4H, -CH 2 -). Example 34: CDC1 3 , 400MHz, 5: 7.26-7.5 5 (m, 11 H, ArH, -CH-), 5.02 (s, 1H, CH), 4.63 (s, 2H, 65 -CH 2 -), 4.01-4.18 (m, 4H, -CH 2 -), 1.18-1.26 (m, 6H, CH 3 ). Example 35: CDC1 3 , 400MHz, 5: 7.52 (d, J=8.6 Hz, 2H, ArH), 7.36 (d, J=8.6 Hz, 2H, ArH), 5.28 (s, IH, CH), 3.74 (s, 3H, -CH 3 ), 3.23 (s, 3H, -CH 3 ) 2.53 (s, 6H, -CH 3 ). Example 36: DMSO-d 6 , 400MHz, S: 11.95 (s, 2H, COOH), 7.57 (d, J=8.6 Hz, 2H, ArH), 7.33 (d, J=8.6 Hz, 2H, ArH), 5.11 (s, 1H, CH), 3.17 (s, 3H, -CH 3 ), 2.41-2.55 (m, 6H, -CH 3 ). 70 Example 37: CDC1 3 , 400MHz, 5: 7.52 (d, J=8.6 Hz, 2H, ArH), 7.45 (d, J=8.6 Hz, 2H, ArH), 7.30 (s, 1H, CH), 7.23 (s, 1H, CH), 5.00 (s, 1H, CH), 4.03-4.20 (m, 4H, -CH 2 -), 3.31 (s, 3H, CH 3 ), 1.18-1.26 (m, 6H, CH 3 ). Reference Example 38: CDC1 3 , 400MHz, 5: 7.09-7.52 (in, 12H, ArH, -CH-), 4.94 (s, 1H, CH), 4.61 (s, 2H, -CH 2 -), 4.01-4.18 (m, 4H, -CH 2 -), 1.14-1.24 (m, 6H, CH 3 ). 75 Reference Example 39: DMSO-d 6 , 400MHz, 5: 11.74 (s, 2H, COOH), 7.29-7.49 (in, 7H, ArH, CH-), 7.15-7.23 (m, 5H, ArH), 4.77 (s, 2H, -CH 2 -), 4.67 (s, 1H, CH). Example 52 Resolution (1) of compound of Ex. 14 )80 1.5 mmol of dimethyl 2-(2-dimethylaminoethyl)-1,6-dimethyl-4-(4-trifluoromethyl phenyl)-1,4-dihydropyridine-3,5-dicarboxylate was dissolved in methanol and 0.5 equivalent of (+)-O,O'-dibenzoyl-D-tartaric acid was added. After a short heating the mixture was evaporated off and the residue was crystallized from diisopropylether-ethyl acetate mixture. The resulting crystalls were recrystallized from ethyl acetate. The dihydropyridine base was obtained after 985 NaHCO 3 treatment. [a]D 2 = - 59.8 (c = 0.5 in methanol) Its HCl salt was recrystallized from methanol-diethyl ether yielding compound Ex. No.: 14/I, mp 210-212'C, [a]D 25 = - 65.8 (c = 0.5 in methanol). The mother liquor was evaporated and basified with NaHCO 3 yielding compound Ex. No.: 14/II [a]25 = + 39.6 (c = 0.5 in methanol) 990 Example 53 Resolution (2) of compound of Ex. 14 It was made similarly to Resolution (1) using (-)-O,O'-dibenzoyl-L-tartaric acid. Mp of the HCl salt 200-203"C, [a]D 25 = - 69 (c = 0.5 in methanol). The NMR (400 MHz, CDC1 3 ) 995 spectra of the enantiomers are similar to that for racemic substance. 39 WO 2013/076516 PCT/HU2012/000126 Biological Examples Example 54 Hsp co-inducing activity The Hsp co-inducing effect of the compounds on stress response was tested on B16 30 mouse melanoma and SHSY5Y human neuroblastoma cell lines stably transfected with Hsp promoter probing plasmids. This kind of promoter probing, using the promoter region of a given gene conjugated with fluorescent protein is used as a best and fastest test system for finding drugs which modulate the activity of the gene followed by the given promoter (Wyshocka et al., Mol. Cel. Biochem. 215:153-156, 2000). 35 The Hsp encoding genes are transactivated through the binding of HSF to the heat shock element found on the DNA upstream of the Hsp genes, in the so called promoter region. In the absence of heat stress, the heat shock factors are present as monomers. Upon heat stress, how ever, the heat shock factors form trimers, which are the active components, able to bind to heat shock elements. Once HSF is bound to the heat shock element in the promoter of Hsp genes, the 10 gene following the promoter region is transcriptionally active. Reporter plasmids, containing the Hsp70 and/or Hsp25 promoter conjugated to either YFP or GFP (yellow or green fluorescent protein), were stably transfected into the cells and the expression of YFP or GFP was followed by flow cytometry. Cells were either kept at 37 0 C or exposed to heat shock at 42'C for 1 hour followed by a 16 hour recovery period at 37 0 C in the 15 presence or absence of different concentrations of the test compound. After recovery the expres sion of YFP or GFP which is in straight correlation with the promoter activity of Hsp70 or Hsp27 genes was followed by measuring the fluorescence intensity of the cells by flow cytome try. Fluorescence intensity is in straight correlation with the amount of fluorescent protein (GFP or YFP) produced under the control of hsp promoter. The mean fluorescence intensity of YFP or 20 GFP produced is shown as "Hsp promoter activity". The Hsp modulating activity for several compounds of the invention are summarised in the following Table 3 and are presented on Figures 1 to 10. Table 3 Hsp modulating activity of the compounds Example No. Hsp70 modulation Other in vitro ef- In vivo efficacy fects 1 +* 0**** Insulin resistance 2 + 0 nd*** 40 WO 2013/076516 PCT/HU2012/000126 Example No. Hsp70 modulation Other in vitro ef- In vivo efficacy fects 3 + 0 nd 4 -- ** 0 nd 6 -- ** 0 nd 7 + 0 nd 8 + 0 nd 10 + 0 nd 11 ++ Hsp25 + nd 12 0 nd 14 ++ 0 Cancer mono 14/I ++ therapy 14/11 ++ 16 ++ 0 nd ++ Cancer mono 17 Hsp25 0 therapy 0 Hsp25 0 UVB protection 23 +++ Hsp27 0 ALS lysosome destabili- Alzheimer 0 zation 24 + 0 nd 25 + 0 nd 26 + 0 nd HSP25 - - 27 - - - cancer combination nd therapy) 41 WO 2013/076516 PCT/HU2012/000126 Example No. Hsp70 modulation Other in vitro ef- In vivo efficacy fects 30 + 0 nd 32 + 0 nd 33 + 0 nd 34 + 0 nd 37 + 0 nd 38 + 0 nd 39 0 nd 40 + 0 nd 41 + 0 nd 42 + 0 nd 44 + 0 nd 45 + 0 nd 47 + 0 nd 49 +++ 0 nd 25 +* co-inducing activity nd*** no data ** silencing activity 0****: with the experimental methods applied no other HSP modulating effects could be identified 30 Fig. 1 demonstrates that application of compound of Example 23 (20pLM) results in ap proximately 20 times higher induction of Hsp70 gene activity when SHSY5Y cells were exposed to elevated temperature (42'C) in the presence of the compound. This compound is a strong con centration dependent co-inducer for Hsp70 stress protein as it does not affect the activity of the 42 WO 2013/076516 PCT/HU2012/000126 promoter of the hsp70 gene at 37 'C in the same cell line. The fluorescence intensity of YFP 35 produced as a result of Hsp70 promoter activity was measured by flow cytometry. Selectivity of the Hsp70 co-inducing activity of compound of Example 23 is shown on Fig. 2: while compound of Example 23 induces a 23 fold increase in HSP70 expression, it has no effect on the expression of Hsp25 in SHSY5Y cells. This compound is a strong and selective co inducer for Hsp70 stress protein as it does not affect the activity of the promoter of the hsp25 40 gene in the same cell line. The fluorescence intensity of GFP and YFP to the values measured in cells treated at 42 0 C without the compound. Selectivity of the Hsp25 co-inducing activity of compound of Ex. 11 is shown on Fig. 3. This compound is a strong, concentration dependent co-inducer for Hsp25 stress protein as it does not affect the activity of the promoter of the Hsp25 gene at 37'C in the same cell line. The 45 fluorescence intensity of GFP produced as a result of Hsp25 promoter activity was measured by flow cytometry. Some of the compounds are Hsp70 selective stress protein response silencers as shown on Fig. 4. Compound of Ex.27 is a strong concentration dependent silencer for stress induced Hsp70 gene activity. The fluorescence intensity of YFP produced as a result of Hsp70 promoter 50 activity was measured by flow cytometry. All above results reveal the unique properties of the compounds of invention i.e., they act only in cells under stress (i.e., when affected by specific and nonspecific stimulus events that disturb its equilibrium and may lead to pathological changes) and they possess a selective activity towards the different type of Hsps. The observed Hsp modulating activity of the com 55 pounds of invention is independent from the Ca 2 ' channel antagonist effect responsible for the antihypertensive activity of the known 1,4-dihydropyridines. For example we found an index of
    EC
    50 HSP-modulating/ Ca2 antagonist effect equal about 1 for Nilvadipine which corresponds to the data that the effective neuroprotective dose for Nilvadipine (8 mg daily; US 8,236,346 B2) is equal to its antihypertensive dose (Int. J. Clinical Pharmacol. Ther., 1997, 35:195-203), )60 whereas the index of EC 50 Hsp modulating/ Ca2 antagonist effect for the compounds of inven tion is at least beyond 10. Thus, the possible separation of an antihypertensive effect permits to provide selected compounds which may be administered when treating pathophysiological con ditions mediated by Hsps, including for example neurodegenerative diseases, cancer, metabolic syndromes, diabetes, obesity, inflammation and skin diseases in doses varying in a large scale )65 without the danger causing hypotension. METHODS Promoter probing experiments 43 WO 2013/076516 PCT/HU2012/000126 Cells were homogenously distributed on 6-well plates in 1 x 10 5 cells/well density. B16 70 pHsp25-GFP and B16-pHsp7O-YFP melanoma cells were grown in RPMI-1640 medium sup plemented with 10% Fetal bovine serum (FBS), penicillin (200 units/ml), streptomycin (200 tg/ml) and 2mM L-Glutamine. For maintaining the SH-SY5Y-pHsp25-GFP and SH-SY5Y pHsp70-YFP neuroblastoma cell lines Dulbecco's modified Eagle's medium (DMEM-F-12) containing 10% FBS, 2mM L-Glutamine, penicillin (200 units/ml), streptomycin (200 tg/ml) and 75 MEM non-essential amino acids were used. Before the treatments both cell lines were incubated at 37 0 C in a saturated humidity atmosphere containing 95% air and 5% C02. After 24h incuba tion cells were pretreated with compounds of the invention in four different concentrations (usu ally in 3; 10; 20 and 50 pM) 30 min before the heat shock at 42'C for I h and then incubated fur ther at 37 0 C for 16h (recovery period). After this procedure cells were trypsinized and suspensed 30 in 500pl serum-free DMEM-F12 medium. The changes in cells' fluorescence were detected us ing BD FACSCalibur flow cytometer. Western blot analysis SY-SY5Y and B16 cells were extracted in NP-40 lysis buffer (PBS pH 7.4, 1% protease B5 inhibitor coctail and 1% Triton X-100). The cell extracts were then constantly agitated at 4'C for 2h. The cell extracts were centrifuged at 12000xg for 30 min and supernatants were saved. After the protein concentration measurement 15pig of total protein was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions according to the method of Laemmli. Proteins were blotted onto PVDF membrane. The blot was incubated 90 overnight at 4'C in the presence of mouse a-Hsp25, a-Hsp70, a-Hsp60 6s a-Hsp90 monoclonal antibodies diluted in PBS. Then, the membrane was washed three times in PBS-0.05% Tween and incubated for 1 h in peroxidase-conjugated anti-mouse IgG antibody diluted 1:50000 in PBS containing 3% non-fat dry milk. The immune complexes were detected with chemo-luminescent substrate of peroxidase according to the supplier's instructions. Images taken from the mem 95 branes were analyzed using AlphaEase FC software. Cytotoxicity test Cells were homogenously distributed on 96-well plates in 5 x 10 3 cells/well density then incubated for 24h at 37 0 C. On the next day cells were treated with compounds of the invention in 00 100nM-200pM concentration range for 24h. The viability of the cells were measured using ala marBlue@ assay kit according to the supplier's instructions. Example 55 44 WO 2013/076516 PCT/HU2012/000126 Insulin resistance )5 Insulin sensitizing activity of the compounds was tested in Zucker obese rat at three doses (10, 30 and 100mg/kg), 6 weeks old Zucker obese (ZO) rats were adapted for a week be fore the administration of the compound. The animals were treated once a day for 5 days with compound Ex. I with 10, 30 and 100 mg/kg dose by stomach probe. The control group was treated with Klucel solution. The animals were kept in metabolic cage during the experiment, 0 their food and drink consumption, the amount of urine and faeces was determined daily. At the end of the treatment period the animals were fasted for 16 hours, the fasting plasma glucose level was determined. At the end the animals were sacrificed and different or gans were taken for Hsp measurement. Zucker obese rat treated with compound of Ex. 1 showed an improved fasting plasma 15 glucose level (A) and elevated Hsp70 amount in brown adipose tissue (B) in a concentration de pendent manner (Fig. 5A , Fig. 5B). Hsp70 level of brown adipose tissue and fasting glucose level in Zucker obese rat treated with compound of Ex. I shows correlation with the applied drug concentration. 20 Example 56 Neuroprotection The neuro- and memoryprotective effect of the compounds of invention was studied on wild and APP mutant transgenic mice. These mice express high levels of mutant beta-amyloid and, with increasing age, develop both substantial amyloid plaque load and memory deficits. 25 Spatial memory disfunction [with the Morris water maze (MWM) behavioural task assay] and histological assays (cell density, astroglial response, tau-pathology, amyloid-histology and den dritic spine density) in the hippocampal (HC) region (key area for the memory-function) were performed. The Morris water navigation task is a behavioral procedure widely used in behavioral 30 neuroscience to study spatial learning and memory. The classic measure of learning is latency, which is the time it takes to find the platform after repeating the task daily. MATERIALS AND METHODS SUBJECTS 35 16 adult female APP+ transgenic and 16 adult female wild type mice were the subjects of the experiment. The animals were housed in sterile mouse cages with a natural dark/light cycle, they had free access to food and water throughout the experiment. After arrival, the mice were daily gently handled for a week. 45 WO 2013/076516 PCT/HU2012/000126 40 TREATMENT In the experiment there were four different animals groups: a wild and an APP mutant group treated with either physiological saline (PB) or the compounds of invention (Ex. 23). The animals were daily treated intraperitoneally for 6 months. 45 SPATIAL NAVIGATION Spatial learning and memory were assessed in a circular pool (diameter: 130 cm, height: 60 cm), filled with water (23±1 'C) and made opaque with milk. The pool was divided into four virtual quadrants, an invisible platform (diameter: 10 cm) was submerged every day in the middle of the first quadrant 2 cm below the water surface, 50 around the pool in two side was black curtain in two side white walls, in all side were colourful distal cues. The animals were i.p injected along the MWM task too. The experiment was an 8-day test and included two parts. In part one on the first 6 days, the platform's position was the same every day. Four different starting points were used, the animals swam every day twice, first from 55 a nearer, and then a farther start position. The animals were placed into the water facing the wall of the pool and were given 90 s to find the platform and 20 s to stay on it. Animals not finding the platform were gently guided and placed on it. In part two on the 8 1h day, after one no swimming day, the platform was taken out from the pool that was the probe trial. The animals were given 60 see to swim, the start point was the farthest place from the platform position (on 60 this day the animals swam once). The data were recorded and evaluated automatically by using a video tracking system. The means of the data from total duration in the arena (sec) were used for statistics; they were compared with one-way analysis of variance, followed by Fisher's LSD post hoc test. 65 RESULTS As it is demonstrated on Fig. 6 all groups needed significantly less time to reach the plat form on the 4 th day then the APP+PB group (F 32 3 =1 6,22; p=0,001). Interestingly, the wild+PB group spent significantly more time in the arena then the wild+compound Ex.23 group (p=0,001). The APP+Ex.23 mice were also better in finding the platform than the wild+PB 70 group (p=0,001) and far better than the APP+PB group. This difference is visible on the 5 th day too (F 3 2
    ,
    3 =3,76; p=0,022) compared the APP+PB with wild+PB (p=0,021) and wild+compound Ex. 23 (p=0,003) groups. The tendency was right on the 6 1h day too, there was marginal signifi cance in time spending in the arena between the groups (p=0,057), however the Ex.23 compund 46 WO 2013/076516 PCT/HU2012/000126 treated animals all spent less time in finding the platforms than PB treated animals and the time 75 was similar for wild+PB to APP+compound Ex.23. There was a significant difference as early as on the 2*h day (F 32 ,3=3,75; p= 0
    ,
    0 2 2), compared the wild+compound of Ex. 23 treated- group to wild+PB (p=0,017) or APP+PB group (p=0,00 6 ) groups. The compound enhances the ability of both the wild type and the memory deficit mutant mice to find the hidden platform in a Morris water maze experiment indicating an improved spatial memory function. 80 Example 57 HISTOLOGY After the Morris water maze task the animals were deeply anesthetized, and transcardialy perfused with 10 ml 4'C phosphate-buffered saline solution (PBS), followed by 30 ml of 4'C 85 paraformaldehyde solution (4% in phosphate buffer, pH 7.4).The brains were removed and post fixed for 24 h in the same fixative (4 'C) and subsequently cryoprotected in 30% sucrose solu tion for 72 h (4'C). Brains were cut on a cryostat in 30 pLm hippocampal coronal sections, and the slices were collected and stored at 4 'C in PBS for free floating immunohistochemistry. Cresyl-violet staining 90 Cresyl violet staining (Nissl staining) is used for neuronal tissue; the stain binds to the acidic components of the neuronal cytoplasm, showing the number of functioning neurons. Slides were stained into the filtered 1% crezyl violet solution for 5 min. and were dehydrated in 50% 70%, 95%, 2X100 % ethanol for 1 minute each. After that slides were placed in xylene for another 10 minutes, and coversliped. 95 GFAP-immunhistochemistry Glial fibrillary acidic protein (GFAP)-immunhistochemistry was utilized for detection of reactive astrogliosis, which is a marker for the inflammatory reaction. The effect was visualised by immunostaining with mouse monoclonal antibody (Chamicon, Billerica, USA) used at 1:500 200 dilution in PBS (pH 7.4). Tau-immunhistochemistry Neurofibrillary tangles (NTFs) are intraneuronal aggregates; these are abnormal accumu lations associated with neurodegenerative diseases. To visualize the presence of these structures, 205 we used for immunostaining human PHF-tau MAb(clone AT100) primer antibody at 1:800 dilu tion in PBS (pH 7.4). Amyloid-immunhistochemistry 47 WO 2013/076516 PCT/HU2012/000126 For the AP immunhistochemistry, rabbit anti-beta 1-42 amyloid primer antibody (WO-2; 210 Genetics Company) at 1:800 dilution was employed. The secondary antibody this time was goat anti-rabbit antibody in 1:200 dilution. The methodological steps in all three immunohistological techniques were the same. Af ter quenching of endogenous peroxidase activity and a blocking step, the sections were incubated overnight at 4'C with the primary antibody in the presence of 20% goat serum and Triton X-100 215 0.2%. On the following day, the sections were washed in PBS and incubated for 1 h at room tem perature with the secondary biotinylated goat anti-mouse antibody (Vector Laboratories, Burlin game, CA, USA, 1:400). The next step was a 1 hour incubation with avidine-biotin complex (Vectastain Elit ABC Kit, Vector Laboratories, Burlingame, CA, USA; 1:400) and detection with nickel-enhanced 3,3'-diaminobenzidine. After immunostaining and washing, all sections 220 were mounted on gelatin-coated slides, air-dried, dehydrated and coverslipped with DPX mount ant for histology (Fluka BioChemika, Buchs, Switzerland). Golgi staining Dendritic spines change their density after a CNS injury, to visualize this effect, we made 225 Golgi staining. After the perfusion we made 100 tm sections from the HC area with vibratome. For Golgi staining methods we used Golgi Stain Kit (FD NeuroTechnologies, USA). The slides were analyzed with confocal light microscopy, we counted dendritic spines 100 jtm long on hip pocampal pyramidal cells, and start point was 100 jim farther from the stoma. 230 STATISTICS The data were recorded and evaluated automatically by using a video tracking system. The means of the data from the first swimmings were used for statistics. For histological analyses HistoQuant program made the counting, except the dendritic spine density. 235 The data were compared with one-way analysis of variance (ANOVA), followed by Fisher's LSD post hoc test. RESULTS The histological studies confirm the behavioural results. The cresyl-violet staining shows 240 that compound of Ex. 23 had neuroprotective effect; there were more alive neurons in compound of Ex. 23 treated animals compared with negative control group, and the result of tau immunohistochemistry was similar: compound of Ex. 23 could inhibit the taupathology, the APP 48 WO 2013/076516 PCT/HU2012/000126 mutant compound of Ex. 23 treated group was in the control rate. The Golgi staining shows also interesting result, like in Morris water maze, the spine density was the highest in the APP mutant 45 compound of Ex. 23 treated group, so we can suppose based on this data, that compound of Ex. 23 somehow can inhibit the spine loss, or had an effect on the neurons, that are in toxic area, to stop degeneration. Example 58 50 Neuroprotection (ALS) Amyotrophic lateral sclerosis (ALS) is a fatal neurodegencrative disease, caused by the death of motor neurons mainly in the spinal cord. The main form of familiar (genetic or inher ited) ALS is caused by the mutation of superoxide dismutase 1 (SODI) gene, which results in extracellular amyloid-like aggregations and progressive neuronal degenerations. Currently there 55 is no effective treatment available, thus a compound which can significantly delay the progress of the disease is of great interest. The "golden standard" of preclinical ALS drug tests is the use of a specific transgenic mouse strain, which harbors high-copy number of human mutated SOD 1 gene, having a mutation of G93A. The effect of Ex. 23 was investigated on lifespan of G93A ALS mouse strain. A total of 60 33 transgenic female mice (B6SJL-Tg(SOD1*G93A)lGur/J) were bred from 4 breeding pairs. The breeding pairs were purchased from the Jackson Laboratory (jax.org). The mice were indi vidually housed in an IVC rack. Standard food pellets and water was available ad libidum. Body weight was monitored daily. The compound Ex.23 was freshly dissolved in saline every day, and was administered daily intraperitoneally at the onset of symptoms in 10 mg/bwkg. Symptom on 265 set was determined according to ALS-TDI neurological score. Mice treated with Ex. 23 lived longer (Fig 10) than untreated mice (mean survival 143 ± 3 days; n= 8 and 132 ± 3 days; n=25, respectively). Example 59/1 270 Anticancer activity The anticancer activity was tested in C57BI/6 mouse (B6), the best known syngeneic mouse model of experimental metastatic melanoma. C57Bl/6 mice injected with B16 melanoma cells subcutaneously or intramuscularly develop primary tumors that, in a part of the recipients, give rise to lung metastases. When the B16 cells are injected intravenously via the tail vein, a 275 fraction of the tumor cells homes directly in the lung, where they develop into multiple inde pendent tumor nodules termed "experimental metastases". Although lung tumors are the most prominent, brain, liver and kidney tumors are also detectable in intravenously injected mice. 49 WO 2013/076516 PCT/HU2012/000126 Since the behavior of the tumor-bearing mice is quite uniform, the model is suitable for simulta neous testing of high numbers of drug candidates in a limited number of experimental animals. 80 The in vivo tumor experiments were performed with cultured B16 cells that were previ ously re-isolated from lung metastatic nodules, therefore their metastatic potential was kept op timal. The tumor cells liberated from the tumor mass by trypsin digestion were expanded in cell culture and stored in aliquots in liquid nitrogen, while the number of in vitro passages was kept to a minimum. In the experiments, B6 mice were injected with 100 000 B16 melanoma cells i.v. 85 via the tail vein. The drug candidates were dissolved in physiological saline then they were ad ministered i.p. in a volume of 100 ul. Daily treatment of tumor bearing mice started at day 7 after the tumor injection. The body weight of the mice was measured at day 1, 7, 14 and 21. The sur vival of the tumor bearing mice was recorded daily. All experiments were performed in accor dance with national and European animal welfare guidelines. To prevent unnecessary suffering, 90 moribund mice were euthanized. The first death in the control group was observed at day 15, the last control mouse died at day 32. The mean survival time was 25.25 +/- 4.13 days, the median survival time was 25.5 days (n=12). The moribund mice autopsied had typically dozens of lung metastasis nodules; in the last one or two days preceding their death some of them showed neurological defects (coordination 295 problems) probably caused by brain metastasis. Treatment with compound of Ex. 14 at 10 mg/kg did not produce drug-related mortality or weight loss. Daily treatment with compound of Ex. 14 from day 7 to day 29 resulted in statistically significant prolongation of survival. Mean survival time has increased from 25.25+/-4.13 days to 29.91+/-3.78 days, p<0,01, two-tailed t-test. In crease in life span = 18%. 300 Treatment with compound of Ex. 17 at 10 mg/kg did not produce drug-related mortality and statistically significant drug related weight loss (LD 50 =150 mg/kg). Daily treatment with compound of Ex. 17 from day 7 to day 18 resulted in statistically significant, dose-dependent prolongation of survival (fig. 8). Mean survival times of mice treated in three different concen trations of Ex 17 are as follows: 1 mg/kg: 31.0+/-3.7days, p<0,001, two-tailed t-test; 3 mg/kg: 305 35.55+/-3.80 days, p<0,001, two-tailed t-test; 10 mg/kg: 38.10+/-10.45 days, p<0,001, two-tailed t-test or non-Mann-Whitney non-parametric test. Increases in life span are 23.1%, 40.8% and 53.7%, respectively. The observed antitumor effect is very pronounced considering the high resistance of melanomas, including the B 16 melanoma. Antitumor agents applied in conventional chemother 310 apy are non-selectively cytotoxic. This sets limits to their use because they are toxic to proliferat ing healthy cells of various organs and thus produce serious unwanted effects. In contrast, com 50 WO 2013/076516 PCT/HU2012/000126 pounds of the invention have no effect on healthy cells, which is a clear advantage in their poten tial therapeutic use. 15 Example 59/2 Anticancer activity - combination therapy Chemotherapy drugs are often more effective when given in combination (combination chemotherapy). The rationale for combination chemotherapy is to use drugs that work by differ ent mechanisms of action, thereby decreasing the likelihood that resistant cancer cells will de 20 velop. When drugs with different effects are combined, each drug can be used at its optimal dose that does not cause intolerable side effects. Ex.27 compound significantly potentiated vincristine (VR) cytotoxicity as demonstrated by a reduction of VR IC 5 0 (ICso: concentration of drug re quired for 50% inhibition of cell growth) compared to VR treatment alone in B16F10 melanoma cells. Ex 27 administered at 1 OpM decreased the IC 50 of VR from 1.3nM to 0.4nM. The advan 325 tage of Ex27 treatment that it has no Ca antagonist effect, therefore it can be applied without unwanted antihypertensive side effects. Example 59/3 Anticancer activity - lysosomal destabilization 330 Emerging evidence argues that both classic apoptosis pathways and lysosomal death pathways must be suppressed for effective development and progression of cancer. Tumor inva sion and metastasis are associated with altered lysosomal trafficking and increased expression of the lysosomal proteases termed cathepsins. Emerging experimental evidence suggests that such alterations in lysosomes may form an "Achilles heel" for cancer cells by sensitizing them to 335 death pathways involving lysosomal membrane permeabilization and the release of cathepsins into the cytosol (Fehrenbacher and Jaattela, Cancer Res April 15, 2005 65; 2993). Normal cells respond to death stimuli by undergoing caspase-dependent apoptosis, the best characterized form of programmed cell death. In contrast, cancer cells frequently escape spontaneous and therapy induced caspase activation due to acquired mutations in the apoptotic machinery. Apoptosis 340 resistant cancer cells are, however, not completely resistant to cell death, but can die via alterna tive cell death pathways often involving non-caspase proteases such as lysosomal cathepsins. Therefore, development of novel anticancer drugs that can trigger alternative death pathways that are independent of commonly mutated apoptosis-regulating genes is of great importance. Inter estingly, transformation and tumor environment enhance the expression of lysosomal cysteine 345 cathepsins. The cathepsins released to the cytosol upon lysosomal membrane permeabilization can trigger caspase-independent and Bcl-2-insensitive apoptosis-like cell death pathways in 51 WO 2013/076516 PCT/HU2012/000126 apoptosis-resistant cells. Siramesine, that is presently being developed as an anticancer drug, de stabilizes lysosomes and activates a caspase-independent cell death (Ostenfeld MS, Fehren bacher N, Hoyer-Hansen M, Thomsen C, Farkas T, Jaattela M. Effective tumor cell death by 50 sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Re search. 2005 Oct 1;65(19):8975-83; Groth-Pedersen L, Ostenfeld MS, Hoyer-Hansen M, Nylandsted J, Jaattela M. Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. Cancer Research. 2007 Mar 1;67(5):2217-25.). As the molecules of the current application also have tumor specific cell killing activity we com 55 pared the lysosomotropic activity of Siramesine with Ex.23. Lysosomal destabilization could be followed by measuring the fluorescence intensity of the pH sensitive FITC-conjugated dextran. Lysosomal pH was determined by allowing the B16F1O melanoma cells to endocytose different amount of FITC-conjugated dextran (40 kDa) (from 10 mg/ml stock) for 24 h. Dextran is ac tively taken up by the cells and ends up in lysosomes. After a 4-hours chase in fresh medium all 60 dextran was considered to have reached the lysosomes and cells were treated either treated with Siramesine (20pm) or Ex.23 (5 pM) for 6 hours. Fluorescence was measured by plate reader us ing an excitation and emission wavelengths of 485 nm and 538 nm respectively. Ex. 23 treatment resulted in a significantly higher fluorescence intensity reporting an elevated pH that is an in creased lysosomal destabilization as compared to Siramesine (Fig. 9). 365 Example 60 Protection against UV induced skin damage To evaluate the effects of systemic administration of Ex.23 on UVB induced edema 16 SKH-1 hairless mice were divided into two groups of 8 animals each. Group 1 mice (Control) 370 were exposed to 230 mJ/cm 2 UVB consecutively for 2 days (a total cumulative UVB dose of 460 mJ/cm2), which evoked edema as described by Athar et al. (Tox. Appl. Pharmacol. 195: 370 378, 2004). Group 2 mice received Ex 23. (10 mg/kg) intraperitoneally 30 min before the first UV treatment. The administration of the compound Ex. 23 was repeated 24 and 48 hours later. UVB-induced skin edema was monitored by measuring the increase in dorsal skin thickness us 375 ing an ultrasound skin scanner (22 MHz). The data show the percent increase in skin thickness compared to the thickness measured before the UVB irradiation. The time-dependent effect of Ex. 23 treatment on UVB induced skin edema as measured by an increase in skin thickness is shown in Fig. 7. The UVB irradiation induced a continuous increase in edema during the 3 days observation period. Systemic administration of Ex.23 sub 380 stantially protected against edema formation. 52
    权利要求:
    Claims (24)
    [1] 1. A compound represented by Formula (I) 0 R 1 0 R 5 N R 4 385 R_ (I) wherein R' is C 6 - 24 aryl group optionally substituted with one or more substituents independently selected from the group consisting of halogen, -NO 2 , straight-chained or branched 390 CI- 6 alkyl, haloCI- 6 alkyl, CI- 6 alkoxy, 5 to 6 membered heteroaryl comprising 1 to 4 nitro gen atoms, -CN, -SO
    [2] 2 NH 2 , C 2 - 6 alkenyl, C 2 - 6 alkynyl, C 3 -scycloalkyl and alk-X-alk group wherein X is 0, S, SO, S02 and alk is CI- 6 alkyl; or 5 to 6 membered heteroaryl group comprising 1 to 3 nitrogen atoms or other heteroatoms like oxygen and sulphur, and com binations thereof; 395 R 2 and R 3 are independently hydrogen or Ci. 6 alkyl group; R 4 and R 5 are independently hydrogen, -CN, CI. 6 alkyl group optionally substituted with amino, mono- or di(CI- 6 alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising additional 1 to 3 N, 0, S heteroa toms and optionally substituted with Ci 6 alkyl or CI. 6 alkoxy group; 400 R is C 1 6 alkyl, C 3 . 7 cycloalkyl, C 3 . 7 cycloalkylCI. 6 alkyl or arylC 1 6 alkyl group; and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enanti omers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, sol vates, esters and prodrugs thereof for use in the therapeutic or prophylactic treatment of a disor der mediated by a heat shock protein. 405 2. The compounds and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceuti cally acceptable salts, solvates, esters and prodrugs thereof of claim 1, wherein the heat shock protein is selected from the group consisting of Hsp-70 and Hsp-25.
    [3] 3. The compounds and stereoisomers including enantiomers, diastereomers, racemic 410 mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceuti cally acceptable salts, solvates, esters and prodrugs thereof of claim 1 or claim 2, wherein the heat shock protein mediated disorder is selected from the group consisting of neurodegenerative 53 WO 2013/076516 PCT/HU2012/000126 diseases, cancerous diseases, metabolic syndromes, lysosomal storage diseases and skin disor ders conditions. 415
    [4] 4. The compounds and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceuti cally acceptable salts, solvates, esters and prodrugs thereof of any one of claims 1 to 3, wherein the treatment further comprises administering at least one therapeutic agent selected from the group consisting of agents useful for the treatment of neurodegenerative diseases, cancerous dis 420 eases, metabolic syndromes, lysosomal storage diseases or skin disorders.
    [5] 5. The compounds and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceuti cally acceptable salts, solvates, esters and prodrugs thereof of claim 4, wherein the treatment fur ther comprises administering at least one therapeutic agent selected from the group consisting of 425 agents useful for the treatment of cancerous diseases.
    [6] 6. The compounds and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceuti cally acceptable salts, solvates, esters and prodrugs thereof of claim 5, wherein the treatment fur ther comprises administering at least one therapeutic agent selected from the group of agents 430 useful for the treatment of cancerous diseases consisting of plant alkaloids.
    [7] 7. The compounds and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceuti cally acceptable salts, solvates, esters and prodrugs thereof of claim 6, wherein the treatment fur ther comprises administering a therapeutically effective amount of vincristine. 435
    [8] 8. A pharmaceutical and optionally cosmetical composition comprising a compound of claim 1 or stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof and one or more pharmaceutically acceptable or cosmeti cally acceptable carriers and/or excipients for use in the therapeutic or prophylactic treatment of 440 a disorder mediated by a heat shock protein.
    [9] 9. The pharmaceutical and optionally cosmetical composition of claim 8 wherein the disorders are selected from the group consisting of neurodegenerative diseases, cancerous dis eases, metabolic syndromes, lysosomal storage diseases and skin disorders conditions.
    [10] 10. A pharmaceutical composition of claim 8 or claim 9 wherein the treatment further 445 comprises administering at least one therapeutic agent selected from the group consisting of agents useful for the treatment of neurodegenerative diseases, cancerous diseases, metabolic syndromes, lysosomal storage diseases or skin disorders. 54 WO 2013/076516 PCT/HU2012/000126
    [11] 11. A pharmaceutical composition of claim 10 wherein the treatment further com prises administering at least one therapeutic agent selected from the group consisting of agents 150 useful for the treatment of cancerous diseases.
    [12] 12. A pharmaceutical composition of claim 11 wherein the therapeutic agent useful for the treatment of cancerous diseases is selected from the group consisting of plant alkaloids.
    [13] 13. A pharmaceutical composition of claim 12 wherein the therapeutic agent useful for the treatment of cancerous diseases is vincristine. 155
    [14] 14. A compound of formula (I) or stereoisomers including enantiomers, di astereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof for use in combination therapy wherein the combination therapy comprises administering an effective amount of a compound of formula (I) or stereoisomers including enantiomers, diastereomers, ra 460 cemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, phar maceutically acceptable salts, solvates, esters and prodrugs thereof to a patient simultaneously, separately or sequentially with a thermal treatment.
    [15] 15. The compound of claim 1 wherein R' is a phenyl group independently optionally substituted with one or two halogen, haloCI 6 alkyl; R2 and R3 are C 1 6 alkyl group; R 4 and R 5 are 465 independently CI. 6 alkyl group optionally substituted with amino, mono- or di(Ci. 6 alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising additional I to 3 N, 0, S heteroatoms and optionally substituted with CI. 6 alkyl or C 1 . 6 alkoxy group; Ri is C 1 . 6 alkyl.
    [16] 16. The compound of claim 1 wherein R 1 is a phenyl group substituted with halo 470 C 1 . 6 alkyl; R2 and R 3 are C 1 . 6 alkyl group; R4 and Rs are independently CI. 6 alkyl group optionally substituted with mono- or di(C 1 . 6 alkyl)amino, or with 5 to 24 membered optionally fused het erocyclic ring attached by nitrogen and optionally comprising additional 1 to 3 N, 0, S heteroa toms and optionally substituted with CI- 6 alkyl or C 1 . 6 alkoxy group; R 6 CI 6 alkyl.
    [17] 17. The compound of claim 1 wherein R' is a phenyl group substituted with fluoro 475 C 1 . 6 alkyl; R2 and R3 are CI. 6 alkyl group; R 4 and R5 are independently C 1 . 6 alkyl group optionally substituted with di(CI. 6 alkyl)amino, or with 5 to 12 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising one additional N heteroatom and optionally sub stituted with C 1 . 6 alkyl or C 1 . 6 alkoxy group; R 6 is C 1 6 alkyl.
    [18] 18. A compound of formula (I) selected from the group consisting of: 480 Dimethyl 1,2,6-trimethyl-4-(4-fluorophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Dimethyl 1,2,6-trimethyl-4-phenyl-1,4-dihydropyridine-3,5-dicarboxylate; Dimethyl 1,2,6-trimethyl-4-(4-methylphenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 55 WO 2013/076516 PCT/HU2012/000126 Dimethyl 1,2,6-trimethyl-4-(4-methoxyphenyl)- 1,4-dihydropyridine-3,5 -dicarboxyl ate; Dimethyl 1,2,6-trimethyl-4-(3-trifluoromethylphenyl)-1,4-dihydropyridine-3,5-dicarboxylate; *85 Dimethyl 1,2,6-trimethyl-4-(2-trifluoromethylphenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Dimethyl 2,6-dimethyl-4-(4-trifluoromethylphenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Dimethyl 1,2,6-trimethyl-4-(4-(1-imidazoly)lphenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Dimethyl 6-(2-pyrrolidin-1-yl-ethyl)-1,2-dimethyl-4-(4-trifluoromethyl-phenyl)-1,4-dihydropyri dine-3,5-dicarboxylate hydrochloride; 90 Dimethyl 2-(2-dimethylaminoethyl)-1,6-dimethyl-4-(4-trifluoromethyl-phenyl)-1,4-dihydropyri dine-3,5-dicarboxylate hydrochloride; Dimethyl 1,2-dimethyl-6-(2-morpholin-4-yl-ethyl)-4-(4-trifluoromethyl-phenyl)-1,4-dihydropy ridine-3,5-dicarboxylate hydrochloride; Dimethyl 1-methyl-2,6-bis-[2-(4-methyl-piperazin-1-yl)-ethyl]-4-(4-trifluoromethyl-phenyl)-1,4 495 -dihydropyridine-3,5-dicarboxylate hydrochloride; Dimethyl 1-methyl-2,6-bis-(2-piperidin-1-yl-ethyl)-4-(4-trifluoromethylphenyl)-1,4-dihydropy ridine-3,5-dicarboxylate dihydrochloride; Dimethyl 4-(2-chlorophenyl)- 1,2,6-trimethyl- 1,4-dihydropyridine-3,5-dicarboxylate; Dimethyl 4-(2-chlorophenyl)-1 -methyl-2,6-bis-(2-pyrrolidin- 1 -yl-ethyl)- 1,4-dihydropyridine 500 -3,5-dicarboxylate dihydrochloride; Dimethyl 4-(2-chlorophenyl)- 1,2-dimethyl-6-(2-morpholin-4-ethyl)- 1,4-dihydropyridine-3,5 -dicarboxylate hydrochloride; Dimethyl 4-(2-chlorophenyl)-1-methyl-2,6-bis-[2-(4-methyl-piperazin-1-yl)-ethyl]-1,4-dihydro pyridine-3,5-dicarboxylate tetrahydrochloride; 505 Dimethyl 4-(2-chorophenyl)-2,6-bis-(2-dimethylamino-ethyl)- 1-methyl-1,4-dihydropyridine -3,5-dicarboxylate dihydrochloride; Dimethyl 4-(4-trifuoromethylphenyl)-2,6-bis-(2-dimethylaminoethyl)-i-methyl-1,4-di-hydropy ridine-3,5-dicarboxylate dihydrochloride; Dimethyl 4-(3,5-difluorophenyl)-1,2,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 510 Dimethyl 4-(3,5-Difluorophenyl)-2,6-bis-(2-dimethylamino-ethyl)-1-methyl-1,4-dihydropyri dine-3,5-dicarboxylate dihydrochloride; Dimethyl 4-(3,5-difluorophenyl)-2-(2-dimethylamino-ethyl)-1,6-dimethyl-1,4-dihydropyridine -3,5-dicarboxylate hydrochloride; Dimethyl 2,6-diethyl-1-methyl-4-(triflouromethyl-phenyl)-1,4-dihydropyridine-3,5-dicarboxy 515 late; 1,2,6-Trimethyl-4-(4-trifluoromethyl-phenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-iso propyl ester 5-methyl ester; 56 WO 2013/076516 PCT/HU2012/000126 Dimethyl 2-(2-dimethylamino-ethyl)- 1 -methyl-6-(2-piperidin- I-yl -ethyl)-4-(4-trifluoro-methyl phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylate dihydrochloride; 520 Dimethyl 2-(2-dimethylamino-ethyl)- 1 -methyl-6-(2-morpholin- 1-yl -ethyl)-4-(4-tri fluoro-methyl phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylate dihydrochloride; Diethyl 1-cyclopropyl-4-(4-trifluoromethylphenyl)-1,4-dihydro-pyridine-3,5-dicarboxylate; Dimethyl 1-benzyl-4-(4-trifluoromethyl-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylate; 1,2,6-Trimethyl-4-(4-trifluoromethyl-phenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid mo 525 nomethyl ester; 1,2,6-Trimethyl-4-(4-trifluoromethyl-phenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid; Diethyl 1-methyl-4-(4-trifluoromethylphenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Dimethyl 2-[2-(1,2,3,4-tetrahidroisoquinolin-2-yl)-ethyl]-1,6-dimethyl-4-(4-trifluoromethyl-phe nyl)- 1,4-dihydropyridine-3,5-dicarboxylate fumarate; 530 Dimethyl 2-[2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)-ethyl]-1,6-dimethyl-4-(4-tri fluoromethylphenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride; Dimethyl 2- [2-(6,7-dimethoxy- 1,2,3,4-tetrahydroisoquinolin-2-yl)-ethyl] -6-(2-dimethyl-amino ethyl)- 1 -methyl-4-(4-trifluoromethylphenyl)- 1,4-dihydropyridine-3,5-dicarboxylate dihydro chloride; 535 Dimethyl 1,2-dimethyl-6-[2-(1,2,4,5-tetrahydrobenzo[d]azepin-3-yl)-ethyl]-4-(4-trifluoromethyl phenyl)-1,4-dihydropyridine-3,5-dicarboxylate fumarate; Dimethyl 4-(furan-2-yl-1,2,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate; Dimethyl 1,2,6-Trimethyl-4-(thiophen-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate; Dimethyl 1,2-dimethyl-6-pyrrolidin- I -ylmethyl-4-(4-trifluoromethylphenyl)- 1,4-dihydropyri 540 dine-3,5-dicarboxylate hydrochloride; Dimethyl 2-cyano-1,6-dimethyl-4-(4-trifluoromethylphenyl)-1,4-dihydropyridine-3,5-dicar boxylate; Dimethyl 1,2-dimethyl-6-piperidin- 1 -ylmethyl-4-(4-trifluoromethylphenyl)- 1,4-dihydropyri dine-3,5-dicarboxylate hydrochloride; 545 Dimethyl 2-(1,2,3,4-tetrahydro-1H-isoquinolin-2-ylmethyl)-1,6-dimethyl-4-(4-trifluorome thylphenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride; Dimethyl 2-cyano-1-methyl-6-pyrrolidin-1-ylmethyl-4-(4-trifluoromethylphenyl)-1,4-dihyd ropyridine-3,5-dicarboxylate hydrochloride; Dimethyl 2-cyano-6-(2-dimethylaminoethyl)- 1 -methyl-4-(4-trifluoromethylphenyl)- 1,4 550 -dihydropyridine-3,5-dicarboxylate hydrochloride; Dimethyl 2-cyano-1,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 57 WO 2013/076516 PCT/HU2012/000126 or stereoisomers, polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof.
    [19] 19. The compound of claim 18 or stereoisomers including enantiomers, di 55 astereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof in enanti omerically enriched form.
    [20] 20. A pharmaceutical and optionally cosmetical composition comprising a compound of claim 18 or stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of 60 enantiomers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof and one or more pharmaceutically acceptable or cosmeti cally acceptable carriers and/or excipients.
    [21] 21. A pharmaceutical compositions comprising a compound of claim 18 or stereoi somers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and 65 combination thereof, as well as polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof in a mixture with an agent useful for the treatment of neurodegenerative diseases, cancerous diseases, metabolic syndromes, lysosomal storage diseases or skin disorders and one or more pharmaceutically acceptable carriers and/or excipients.
    [22] 22. A pharmaceutical composition of claim 21 wherein the treatment further com 70 prises administering at least one therapeutic agent selected from the group consisting of agents useful for the treatment of cancerous diseases.
    [23] 23. A pharmaceutical composition of claim 22 wherein the therapeutic agent useful for the treatment of cancerous diseases is selected from the group consisting of plant alkaloids.
    [24] 24. A pharmaceutical composition of claim 23 wherein the therapeutic agent useful 75 for the treatment of cancerous diseases is vincristine. 58
    类似技术:
    公开号 | 公开日 | 专利标题
    US10660789B2|2020-05-26|1,4-dihydropyridine derivatives with HSP modulating activity
    Carmo Carreiras et al.2013|The multifactorial nature of Alzheimer’s disease for developing potential therapeutics
    EA026559B1|2017-04-28|Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
    EP2049525B1|2009-12-30|N-|-1h-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof
    KR101506062B1|2015-03-25|Combined use of angiogenesis inhibitor and taxane
    CN109563047A|2019-04-02|Containing silicon atom according to cutting down Kato analog
    EP2620429A1|2013-07-31|Hydroxylamine compounds and methods of their use
    WO2016105468A1|2016-06-30|Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
    MX2014013374A|2015-01-16|Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1.
    KR20150020169A|2015-02-25|Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
    NO330754B1|2011-07-04|Quinoline derivatives, processes for the preparation of such, pharmaceutical formulations comprising such, such compounds in medical therapy, and such compounds for the treatment of disease
    NO20071577L|2007-05-02|Biphenyloxyacetic acid derivatives for the treatment of respiratory diseases
    EP2555768A2|2013-02-13|Ire-1inhibitors
    CN103459382B|2016-06-29|For suppressing the heterocyclic compound of PASK
    EP3691638A1|2020-08-12|Compounds, compositions and methods for increasing cftr activity
    EP2166860B1|2016-09-21|Novel heterocycle compounds and uses thereof
    US20080200405A1|2008-08-21|Drug Resistance Reversal In Neoplastic Disease
    AU2004317879A1|2005-10-13|Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
    TW200800193A|2008-01-01|Therapeutic agent for dermatitis
    US20160354352A1|2016-12-08|Method of treating inflammatory bowel disease comprising administering a pharmaceutical composition comprising a 6-aminopyridin-3-ol compound or a pharmaceutically acceptable salt thereof as an active ingredient to a subject
    ES2788660T3|2020-10-22|2,3-dihydro-1h-inden-1-one derivatives as orphan receptor antagonists related to gamma retinoic acid | for the treatment of multiple sclerosis
    CN109180670A|2019-01-11|Imino group thiadiazine dioxide derivative and application thereof
    EP2970118B1|2018-09-12|Compounds for the treatment of neurological disorders
    KR20190035386A|2019-04-03|A composition for preventing or treating neurodegenerative diseases comprising benzene diamine derivates
    CN109180672A|2019-01-11|Imino group thiadiazine dioxide derivative and application thereof
    同族专利:
    公开号 | 公开日
    HUE046668T2|2020-03-30|
    CN103998038A|2014-08-20|
    CN110606822A|2019-12-24|
    CA2854252A1|2013-05-30|
    US10660789B2|2020-05-26|
    AU2012342226B2|2017-09-28|
    WO2013076516A1|2013-05-30|
    JP6073913B2|2017-02-01|
    CA2854252C|2016-11-29|
    JP2014533717A|2014-12-15|
    US10258498B2|2019-04-16|
    EP2782573B1|2019-10-09|
    EP2782573A1|2014-10-01|
    US20190192336A1|2019-06-27|
    US20140315893A1|2014-10-23|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    DE1923990C3|1969-05-10|1978-11-23|Bayer Ag|Process for the preparation of N-substituted M-dihydropyridine-S.S-dicarboxylic acid esters|
    DE2210672C3|1972-03-06|1980-03-20|Bayer Ag, 5090 Leverkusen|N-substituted asymmetrical 1 ^ -dihydropyridine-S ^ -dicarboxylic acid esters, process for their preparation and their use as medicaments|
    JPS5547656A|1978-09-29|1980-04-04|Dainippon Pharmaceut Co Ltd|2--1,4-dihydropyridine derivative and its derivative|
    US4780538A|1986-02-12|1988-10-25|Merck & Co., Inc.|Process for 1,4-dihydropyridine compounds using a titanamine catalyst|
    EP0330470A3|1988-02-24|1992-01-02|Ajinomoto Co., Inc.|1,4-dihydropyridine derivatives useful against tumour cells|
    JPH01316357A|1988-02-24|1989-12-21|Ajinomoto Co Inc|Agent for conquering resistance to cancer and novel 1,4-dihydroxypyridine derivative|
    DE4011695A1|1990-04-11|1991-10-17|Bayer Ag|USE OF N-ALKYLATED 1,4-DIHYDROPYRIDE INDICARBOXIC ACID ESTERS AS DRUGS, NEW COMPOUNDS AND METHOD FOR THEIR PREPARATION|
    GB9119983D0|1991-09-19|1991-11-06|Erba Carlo Spa|Dihydropyridine derivatives useful in antitumor therapy|
    DE4200714A1|1992-01-14|1993-07-15|Bayer Ag|SPECIAL 1,4-DIHYDROPYRIDINE-3,5-DICARBONE ACID ESTERS, PROCESS FOR ITS PREPARATION AND ITS PHARMACEUTICAL USE|
    DE4328884A1|1993-08-27|1995-03-02|Bayer Ag|Use of N-alkylated 1,4-dihydropyridinecarboxylic acid esters as medicaments|
    DE4430094A1|1994-08-25|1996-02-29|Bayer Ag|Use of 3,5-dicarboxylic acid ester-1,4-dihydropyridines as a drug|
    DE4444864A1|1994-12-16|1996-06-20|Bayer Ag|Use of 5-acyl-1,4-dihydropyridines|
    LV12200B|1997-07-03|1999-04-20|Gunārs DUBURS|Antidiabeic agent|
    US6306853B1|1998-02-10|2001-10-23|Nikken Chemicals Co., Ltd.|1,4-Dihydropyridine derivatives|
    AU2003227610A1|2002-04-12|2003-10-27|Multimmune Gmbh|Non-toxic amounts of protein-aggregating substances stimulate hsp70 expression and function as anti-tumor agents|
    TW200528107A|2003-11-25|2005-09-01|Nissan Chemical Ind Ltd|T-type calcium channel inhibitor|
    JP2007230869A|2004-04-05|2007-09-13|Takeda Chem Ind Ltd|Aldosterone receptor antagonist|
    US20060188938A1|2005-01-07|2006-08-24|Mullan Michael J|Compounds for inhibiting beta-amyloid production and methods of identifying the compounds|
    US7851431B2|2005-07-27|2010-12-14|Prescription Dispensing Laboratories|Treatment of actinic keratoses with calcium channel blockers|
    US20100048638A1|2008-07-01|2010-02-25|Zacharon Pharmaceuticals, Inc.|Heparan sulfate inhibitors|
    CN101897705B|2009-05-27|2014-04-09|中国科学院上海生命科学研究院|Compound having function of resisting tumor activity|
    CN103998038A|2011-11-24|2014-08-20|里皮达特发展研究及咨询公司|1,4-dihydropyridine derivatives with HSP modulating activity|CN103998038A|2011-11-24|2014-08-20|里皮达特发展研究及咨询公司|1,4-dihydropyridine derivatives with HSP modulating activity|
    US20200000822A1|2017-02-23|2020-01-02|Board Of Regents, The University Of Texas System|Methods of treatment for cancer, sterol homeostasis, and neurological diseases|
    CN109721596B|2017-10-27|2020-12-18|广东东阳光药业有限公司|Phenyl-substituted dihydropyridines and their use|
    CA3106195A1|2018-07-12|2020-01-16|The Texas A&M University System|Compositions for the treatment of copper deficiency and methods of use|
    法律状态:
    2018-01-25| FGA| Letters patent sealed or granted (standard patent)|
    2018-06-14| PC| Assignment registered|Owner name: RICHTER GEDEON NYRT. Free format text: FORMER OWNER(S): LIPIDART KUTATO FEJLESZTO ES TANACSADO KFT. |
    优先权:
    申请号 | 申请日 | 专利标题
    HUHUP1100646||2011-11-24||
    HU1100646||2011-11-24||
    PCT/HU2012/000126|WO2013076516A1|2011-11-24|2012-11-22|1,4- dihydropyridine derivatives with hsp modulating activity|
    [返回顶部]